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 Type 2 diabetes (T2D) is a complex metabolic disorder characterized by hyperglycemia. 
Exposures to environmental toxicants are less studied in the context of T2D, but these toxicants, 
alone or in conjunction with other environmental and lifestyle factors, may play a contributing 
role to the development of T2D. Numerous population studies have found an association 
between exposure to inorganic arsenic (iAs) in drinking water and an increased incidence or 
prevalence of T2D. These studies also indicate that metabolism of iAs into monomethyl-As 
(MAs) and dimethyl-As (DMAs) metabolites, which facilitates clearance of iAs from the body, 
influences individual susceptibility to adverse effects of iAs exposure. Population studies of iAs 
exposure point to defects in insulin secretion as being the primary cause of metabolic 
dysfunction, and the impairment of insulin secretion has been validated in lab studies. While the 
exact mechanism by which iAs affects pancreatic beta cells and insulin secretion is unknown, 
microRNAs (miRNAs) have emerged as potential drivers. MiRNAs are environmentally 
responsive, short non-coding RNAs that are important components of gene regulatory networks 
involved in T2D. While miRNA expression changes have been observed in the presence of some 
metals including arsenic, and have specifically been shown to play a role in metabolism and 
glucose homeostasis, the role of miRNAs in the pancreas in the context of environmental metal 




exposed to iAs through drinking water, as well as an in vitro cell line to identify miRNAs that 
link iAs exposure to diabetes. I identified a novel association between a methylated metabolite of 
iAs and 6 circulating plasma miRNAs, several of which have known links to diabetes. I also 
found that the inhibition of insulin secretion from beta cells exposed to iAs was concurrent to the 
upregulation of miR-146, an important regulator of several genes involved in the pathogenesis of 
T2D. Lastly, I examined the enhancer profile of pancreatic beta cells exposed to iAs or MAs and 
found that both exposures were associated with decreased activity of transcriptional regulatory 
elements enriched in binding sites for important transcription factors critical in maintaining 
pancreatic beta cell identity and function, including Pdx1. The results from this body of work 
contribute to the field of toxicology and environmental health by addressing major knowledge 
gaps in gene regulation and noncoding RNAs, and warrant further study and validation in the 
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CHAPTER 1: INTRODUCTION 
 
Type 2 diabetes (T2D) is a complex metabolic disorder characterized by hyperglycemia 
that is generally caused by defects in insulin production, secretion, and/or systemic action. While 
both genetics and lifestyle components, such as diet and exercise, can significantly increase risk 
for T2D, chronic exposure to chemical diabetogens is less studied in the context of T2D etiology. 
Inorganic arsenic (iAs) is one such environmental diabetogen. The Environmental Protection 
Agency (EPA) and the Agency for Toxic Substances and Disease Registry (ATSDR) rank 
arsenic as first on the U.S. Priority list of Hazardous Substances (Agency for Toxic Substances 
2007). Over 300 million people across more than 70 countries are exposed to iAs in their 
drinking water, and chronic exposure to iAs is associated with numerous adverse health effects 
including cancer, cardiovascular disease, hypertension, and, notably, diabetes (Agency for Toxic 
Substances 2007).  
 Though the exact mechanism by which arsenic influences metabolic disorders is 
unknown, dysregulation of microRNAs (miRNAs) has emerged as a potential mode of action. 
miRNAs are short, non-coding molecules that negatively regulate gene expression at the post-
transcriptional level. They are involved in the control of metabolic processes associated with 
impaired glucose tolerance and diabetes, such as gluconeogenesis in the liver and insulin 




the development and progression of iAs-associated diabetes could open a new avenue for 
therapeutic options. 
 
1.1 Sources of iAs exposure 
Sources of human exposure to iAs are both natural and anthropogenic. Arsenic is a 
naturally occurring metalloid and is present mainly as a sulfide in over 200 mineral species 
containing a mixture of metals, including silver, lead, copper, nickel, antimony, cobalt, and iron 
(WHO 2000; Gomez-Caminero, A, P Howe, M Hughes, E Kenyon, DR Lewis, M Moore, J Ng 
2001). Arsenic is released into air, water, and soil as a result of volcanic activity, leaching of 
arsenic from soil to groundwater, and industrial processes (WHO 2000). Approximately one-
third of the global atmospheric flux of arsenic (7900 tons per year) is estimated to be from 
natural sources with volcanic activity being the most significant contributor (WHO 2000; 
Gomez-Caminero, A, P Howe, M Hughes, E Kenyon, DR Lewis, M Moore, J Ng 2001). The rate 
of its release from minerals can be enhanced by mining activities, exposing the minerals to 
weathering processes during excavation and leading to the accumulation of iAs in soil and water. 
iAs is readily metabolized by microorganisms, plants, and animals into organoarsenic species, 
including volatile arsenicals that can enter the atmosphere (WHO 2000; Gomez-Caminero, A, P 
Howe, M Hughes, E Kenyon, DR Lewis, m Moore, J Ng 2001). 
Arsenic and arsenic-containing compounds have been produced and used commercially 
for centuries (ATSDR 2007). Major anthropogenic sources of arsenic are associated with mining, 
smelting of non-ferrous metals and burning of fossil fuels, which lead to the contamination of 
air, water, and soil. Furthermore, the historical use of arsenic-containing pesticides and 




agricultural land contaminated (WHO 2000; Gomez-Caminero, A, P Howe, M Hughes, E 
Kenyon, DR Lewis, M Moore, J Ng 2001). Past and ongoing uses of arsenic include 
pharmaceuticals, wood preservatives, agricultural chemicals, and applications in the mining, 
metallurgical, glass-making, and semiconductor industries (ATSDR 2007). In most regions 
though, drinking water is the most common source of iAs for humans (International Agency for 
Cancer Research 2002), followed by agricultural products contaminated with iAs or 
organorasenicals. 
Once ingested, iAs is methylated to either trivalent AsIII- or pentavalent AsV-containing 
metabolites, including methylarsenite (MAsIII), dimethylarsenite (DMAsIII), methylarsenate 
(MAsV), and dimethylarsenate (DMAsV).(H. Vasken Aposhian et al. 2000; Gong et al. 2002; 
Drobna et al. 2006, 2009b; Dheeman et al. 2014) A critical enzyme in this process is arsenic (+3 
oxidation state) methyltransferase (AS3MT), a member of the large superfamily of S-
adenosylmethionine (SAM)-dependent enzymes (Styblo et al. 2000a)(Figure 1.1). These 
reactions appear to occur irrespective of whether the means of exposure is inhalation, ingestion, 
or a parenteral route (ATSDR 2007). The methylated arsenic species are more readily excreted in 
urine, resulting in lower tissue retention of iAs. Therefore, the methylation of iAs has been 
viewed historically as a detoxification process (Marafante and Vahter 1984, 1987; Marafante et 
al. 1985). This notion, however, is being called into question, as there have been recent studies 
showing that the trivalent methylated species, MAsIII and DMAsIII, are more toxic and 
biologically active than unmethylated iAs in laboratory models (Petrick et al. 2000, 2001; Styblo 
et al. 2000b). In addition, growing evidence suggests that MAsIII and DMAsIII also contribute to 
the adverse health effects of chronic iAs exposure in humans, including the diabetogenic effects 





Figure 1.1. Oxidative (A) and reductive (B) models of iAs methylation (Drobna et al. 2009a)  
 
1.2 Arsenic exposure and public health 
The Environmental Protection Agency (EPA) and the Agency for Toxic Substances and 
Disease Registry (ATSDR) rank arsenic as first on the U.S. Priority list of Hazardous Substances 
(Agency for Toxic Substances 2007). Both the inhalation and ingestion of iAs have been linked 
to an increased risk of cancer of the lungs, urinary bladder, kidney, skin, liver, and prostate 
(IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 2004). Several 
studies have revealed an elevated cancer risk for populations exposed to varying amounts of iAs 
from industrial emissions (Lubin et al. 2000; Abernathy 2001; International Agency for Cancer 
Research 2002; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 
2004). In addition, an association between various cancers and contaminated drinking water 
(IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 2004) has been 




1988),  Japan (Tsuda et al. 1995), United States (Bates et al. 1995), and parts of South America 
(Rivara et al.; Hopenhayn-Rich et al. 1998). Recent reports from the United Nations International 
Children's Emergency Fund (UNICEF) indicate that over 140 million people across more than 70 
countries are exposed to iAs in their drinking water (Murcott 2012). In the United States alone, 
there are over 13 million people drinking water containing iAs at levels higher than the current 
EPA maximum contaminant level of 10 µg As/L, i.e., 10 parts per billion (ppb)(Agency for 
Toxic Substances 2007). While most dietary arsenic is derived from saltwater fish and seafood 
(Dabeka et al.; Wang et al. 2013), only a small proportion occurs in the inorganic form (Li et al. 
2003; Schaeffer et al. 2005). Significant amounts of iAs are absorbed when agricultural plants 
are grown in or watered with iAs-contaminated water, and so the most abundant sources of 
dietary iAs include rice, grains, and flour (Schoof et al. 1999). Chronic exposure to iAs has been 
associated with numerous adverse health effects in addition to cancer, including cardiovascular 
disease (Tseng et al. 1996; Chiou et al. 1997), hypertension (Chen et al. 1995; Rahman et al. 
1999), and recently, T2D (Tseng 2007; Maull et al. 2012). 
Type 2 diabetes is a complex metabolic disorder characterized by hyperglycemia that is 
generally caused by defects in insulin production, secretion, and/or systemic action.(Paul et al. 
2007a) T2D can lead to numerous long term complications such as cardiovascular disease, nerve 
and kidney damage, chronic inflammation, or diabetic ketoacidosis (Paul et al. 2007a). Risk 
factors for T2D include both genetic and environmental variables (Romao and Roth 2008; Murea 
et al. 2012). Over 80 distinct genetic loci have now been identified across diverse human 
populations that significantly increase risk for T2D (Fuchsberger et al. 2016). While lifestyle 




that obesity often precedes some forms of T2D, chronic exposures to environmental chemicals 
are less studied in the context of T2D etiology. 
The first studies of an association between arsenic exposure and T2D took place in 
Europe in the mid-1990s and were focused on occupational exposure (Rahman and Axelson 
1995; Rahman et al. 1996; Jensen and Hansen 1998) to iAs, as well as in Taiwan and Bangladesh 
in the late 1980s to mid-1990s, which centered on iAs exposure through drinking water (Lai et 
al. 1994; Rahman et al. 1998; Tseng et al. 2000). Findings in other studies were inconsistent 
(Chen et al. 1995; Longnecker and Daniels 2001; Tseng et al. 2002a), possibly due to variation 
in exposure measurements and lack of standardized diagnostic criteria, especially for populations 
with low-to-moderate iAs levels in drinking water (<150 ppb). Therefore, the association with 
T2D was viewed as ambiguous at best. However, several of these studies assessed iAs exposure 
indirectly by measuring arsenic levels in drinking water sources rather than using biomarkers of 
exposure (Lai et al. 1994; Tseng et al. 2000). Also, some of these studies ascertained diabetes 
status based on self-reporting or death certificates (Rahman et al. 1996; Lewis et al. 1999). More 
recent studies that use direct, quantitative methods to measure iAs exposure, and that include 
specific clinically-relevant criteria for diabetes, consistently find a significant association with 
diabetes at even low-to-moderate exposure levels (Coronado-González et al. 2007; Navas-Acien 
et al. 2008, 2009; Del Razo et al. 2011; James et al. 2013; Bräuner et al. 2014; Kuo et al. 2015b). 
For a thorough summary of these studies we refer the reader to the following review articles 
(Tseng et al. 2002b; Navas-Acien et al. 2005; Maull et al. 2012). Notably, a review by the 
National Toxicology Program concluded that while further research is needed, recent studies of 
low-level exposure using improved measures of exposure and outcome support an association 




epidemiological connection between iAs exposure and T2D, it is of substantial interest to 
determine the means by which iAs contributes to T2D pathophysiology.  
1.3 Arsenic and T2D pathophysiology  
Laboratory studies have shown that 48-hour exposure to 2 µM of iAsIII, or 0.1 µM of 
MAsIII or DMAsIII, is sufficient to impair the in vitro function of pancreatic islets isolated from 
C57BL/6 mice as measured by glucose stimulated insulin secretion (GSIS) (Douillet et al. 2013). 
In two other studies, 5 µM of sodium arsenite (iAsIII) for 72 hours in primary rat pancreatic β 
cells reduced insulin mRNA expression (Diaz-Villasenor et al. 2006) and 0.5 µM sodium 
arsenite in a rat insulinoma cell line suppressed Ca2+ influx, thereby inhibiting insulin vesicle 
packaging and impairing GSIS (Díaz-Villaseñor et al. 2008). In a separate report, a 96 hour, 0.25 
µM iAsIII treatment of a rat insulinoma (INS-1-832/13) cell line was shown to induce a 
significant Nrf2-mediated antioxidant response, which suppresses endogenous reactive oxygen 
species that are thought to be involved in insulin secretion (Fu et al. 2010). 
Aside from pancreatic β-cell defects, iAsIII exposure has been shown to inhibit 
differentiation of fat cells, or adipocytes, which play a major role in glucose utilization and 
energy homeostasis. Specifically, 3T3-L1 pre-adipocyte cells treated in vitro with 6 µM iAsIII for 
two months decreased expression of PPARγ (Wauson et al. 2002), which drives adipocytic 
differentiation (Tontonoz et al. 1994). Impaired PPARγ signaling in adipose can lead to reduced 
insulin sensitivity (Wauson et al. 2002). iAsIII and its trivalent methylated metabolites (Walton et 
al. 2004) were also shown to inhibit insulin signaling and insulin-stimulated glucose uptake in 




as in murine hepatocytes (Zhang et al. 2017), suggesting that in addition to beta cell impairment, 
iAs exposure can also result in insulin resistance 
In the liver, 3 mg/L of sodium arsenite enhances gluconeogenesis in both normo-
glycemic C57BLKS/J (db/m) and diabetic C57BKS/Leprdb (db/db) mice, at least in part by 
increasing levels of protein tyrosine phosphatase-1B (Ptp1b)(Liu et al. 2014a), which is a known 
suppressor of hepatic insulin signaling (González-Rodríguez et al. 2010). Another study in 
estrogen deficient ICR/HaJ mice reported that 0.05 ppm iAs in drinking water for 6 weeks can 
stimulate the transcription of phosphoenolpyruvate carboxykinase (Pepck) transcription and 
thereby likely promote hepatic glucose production (Huang et al. 2015). 
Lastly, iAs is a potent endocrine disruptor of estrogen receptor (ER)-mediated gene 
regulation, and has been shown to alter steroid hormone receptor (SR)-mediated signaling at very 
low, environmentally relevant concentrations in both cell culture and whole-animal models 
(Kaltreider et al. 2001; Bodwell et al. 2006; Davey et al. 2007). These receptors play a critical 
role in normal biology and development (Bondesson et al. 2015), including energy balance and 
glucose homeostasis (Ropero et al. 2008). Though the exact mechanisms of action remain 
unknown, multiple studies support an association between endocrine disruptors and metabolic 
syndrome, (Wang et al. 2014a; Song et al. 2016) which may partially explain how chronic 
exposure to iAs has been associated with pathophysiological illnesses such as T2D.  
Taken together, these studies show that the epidemiological link between iAs exposure 
and T2D may be mediated in part by iAs-exposure-associated defects in several different cell 
types and tissues, including islets, adipose, and liver, leading to either impaired insulin secretion 
or insulin resistance. For more details on these studies, we refer the reader to the following 




molecular mechanisms of these defects remain poorly characterized and merit deeper 
investigation. 
1.4 Candidate mechanisms underlying effects of arsenic on diabetes pathways 
The precise mechanisms by which arsenic affects T2D-relevant pathways remain unclear. 
Several studies have observed reproducible changes in gene expression upon iAs exposure in 
lymphocytes (human), macrophages (human), and liver (mouse) (Xie et al. 2007; Andrew et al. 
2008; Bourdonnay et al. 2009). The latter study in mouse liver also reported systematic changes 
in DNA methylation profiles upon iAs exposure. Recently, an association between levels of iAs 
exposure and DNA methylation patterns has been reported in studies of human populations as 
well (Pilsner et al. 2007; Smeester et al. 2011; Rottiers and Näär 2012; Bailey et al. 2013). For 
example, a study of iAs-exposed human populations in Bangladesh reported a positive 
association between global hypermethylation of peripheral blood leukocyte (PBL) DNA and iAs 
concentrations in urine and plasma in individuals with plasma folate concentrations > 9 nmol/L 
(Pilsner et al. 2007, 2009). These findings were supported by a study of a Mexican cohort, in 
which the promoters of 183 genes were differentially methylated in individuals exhibiting iAs-
associated skin lesions; most of the affected genes have known links to cardiometabolic 
disorders (Smeester et al. 2011).  
Altered DNA methylation status can influence transcription of not only nearby protein-
coding genes, but also non-coding RNAs (ncRNAs). In more recent years, one particular class of 
ncRNAs, microRNAs (miRNAs), has emerged both as responsive to iAs exposure and, 
independently, as candidate drivers of phenotypes in metabolic disorders such as T2D (Marsit et 




al. 2011b; Ghaffari et al. 2012; Rottiers and Näär 2012; Kriegel et al. 2012; Ramirez et al. 2013; 
Sturchio et al. 2014). Researchers in this field are just beginning to investigate whether miRNAs 
may serve as mechanistic links between arsenic exposure and diabetes. Given the heightened 
interest in miRNA-based diagnostic and therapeutic strategies, (Trajkovski et al. 2011a; Frost 
and Olson 2011; Fu et al. 2012; Choi et al. 2013; Kurtz et al. 2015a) this area represents highly 
translational research that could yield findings of potential clinical utility. 
1.5 microRNAs: potential mechanistic links 
miRNAs are short, non-coding, RNA molecules about 22 nucleotides in length, that are 
transcribed predominantly by RNA polymerase II and negatively regulate gene expression at the 
post-transcriptional level (Liu et al. 2008). At present, more than 1,000 miRNAs have been 
identified in the human genome. Over the last decade, it has become apparent that miRNAs play 
a crucial role in diverse biological processes predominantly through the fine-tuning of gene 
networks (Tabet et al. 2014; Salunkhe et al. 2015; Sollome et al. 2016). miRNAs reside either in 
protein coding genes where they are sometimes transcribed along with the host gene, or can be 
found in non-protein coding regions with their own independent transcription units.  
Transcription leads to a primary miRNA transcript (pri-miRNA), which can range anywhere 
from a few hundred base pairs (bp) to hundreds of kilobases in length (Saini et al. 2008). In the 
canonical miRNA biogenesis pathway, stretches of sequence in the pri-miRNA that form 
hairpin-like secondary structures are recognized and excised in the nucleus by the 
microprocessor complex involving DGCR8 and DROSHA. The resulting sequence, known as a 
precursor miRNA (pre-miRNA), is approximately 70-100 nucleotides in length and is exported 
from the nucleus into the cytoplasm by Exportin 5-Ran-GTP (Liu et al. 2008). Once in the 




about ~22 base pairs in length. One or both of the strands is independently loaded onto the RNA-
induced silencing complex (RISC), at which point the miRNA is ready to guide and tether the 
main effector protein in RISC, Argonaute (Ago), to target RNA sequences.(Liu et al. 2008) The 
stability of binding of the miRNA-RISC to a target depends in part on the extent of sequence 
complementarity between the miRNA and the target RNA. Once Ago is tethered to a target 
mRNA it confers gene silencing by translational repression and/or mRNA degradation (Figure 
1.2 ). miRNAs can also be secreted into circulation and serve as plasma biomarkers (Chen et al. 
2008; Elamin et al. 2011) of disease (Hulsmans and Holvoet 2013; Hayes et al. 2014). The 
stability of miRNAs in circulation arises from the fact that they are protected by microparticles, 
including exosomes and lipoproteins. Changes in the levels of circulating miRNAs can be 
predictive of disease onset and/or disease subtype/severity, which could lead to early diagnosis 







Figure 1.2 Simplified illustration depicting canonical microRNA biogenesis.  
In recent years, researchers have studied changes in tissue miRNA expression in response 
to external stimuli, including environmental toxicants (Schembri et al. 2009; Vrijens et al. 2015; 
Sollome et al. 2016). Arsenic and other compounds have been associated with altered miRNA 
expression both ex vivo and in vitro (Marsit et al. 2006; Liu et al. 2011; Sollome et al. 2016).  For 
example, in the peripheral blood of steel workers, the levels of two miRNAs linked to tumor 
progression, miR-222 and miR-21, were associated with the level of exposure to a combination 
of iAs, iron, lead, and other metals in particulate matter (Bollati et al. 2010). A recent literature 
review by Sollome et al. indicated that the levels of over 20 additional miRNAs have been 




(Sollome et al. 2016). These results suggest that iAs and other co-occurring environmental toxins 
can work alone or cooperatively to modulate the expression of miRNAs. 
miRNAs in a number of metabolic tissues, including liver, adipose, and islets, have been 
linked previously to the pathogenesis of diabetes (Sethupathy 2016). Several miRNAs have been 
implicated in the regulation of insulin signaling in the liver, adipose, and skeletal muscle, as well 
as insulin production and secretion in the pancreatic islets (Poy et al. 2004, 2009; Plaisance et al. 
2006; El Ouaamari et al. 2008; Lovis et al. 2008; Tang et al. 2009; Fred et al. 2010). Five 
prominent examples from the literature are described below: 
• In vivo studies in mice have revealed that miR-29 controls both lipogenic and insulin 
signaling pathways in the liver (Kurtz et al. 2015a; Dooley et al. 2016). miR-29 has also 
been shown to respond to glucose and regulate insulin secretion in rodent β-cell-like 
lines, potentially in part through regulation of monocarboxylate transporter 1 (Mct1) 
(Pullen et al. 2011a).  
 
• Knockout and over-expression studies in mice showed that miR-7 regulates a molecular 
network that controls insulin granule exocytosis and pancreatic β-cell identity (M. et al. 
2014). Moreover, miR-7 appears to play a role in β-cell adaptation during the 
development of diabetes.  
 
• miR-24 was identified as a master regulator of β-cell proliferation and insulin secretion in 
vitro, in large part via its direct control of Hnf1a and Neurod1 (Zhu et al. 2013), encoded 
by two different genes in which specific mutations are known to cause maturity-onset 





• miR-375 was first shown to suppress GSIS in the MIN6 mouse β-cell-like cell line in part 
by targeting and repressing myotrophin (Mtpn) (Poy et al. 2004). Subsequent studies 
revealed that miR-375 knockout mice exhibit altered pancreatic -cell to β-cell ratios, 
increased fasting and fed plasma glucagon levels, and increased gluconeogenesis and 
hepatic glucose output (Poy et al. 2009). 
 
• In separate studies, miR-34a was shown in obese mice to drive metabolic dysfunction in 
both liver and adipose by suppressing the gene sirtuin 1 (Sirt1) and also by inhibiting 
fibroblast growth factor 19 and 21 (Fgf19 and Fgf21) signaling (Fu et al. 2012, 2014; 
Choi et al. 2013). These reports suggested that miR-34a may be an attractive therapeutic 
target for obesity and related metabolic diseases.  
Notably, most of these miRNAs have been identified as being responsive to arsenic in 
different tissues and cell lines (Table 1). For example, both miR-24 and miR-29 were shown to 
be significantly upregulated in Human Umbilical Vein Endothelial Cells (HUVEC) after 
treatment with 20 µM iAs for 24 hours (Sollome et al. 2016). miR- 29a was also altered in 
HepG2 hepatoma cells after treatment with 2 µM arsenic trioxide 24 hours (Meng et al. 2011). 
Also, in another study, 0.5 µM arsenite treatment of keratinocytes for 24 hours led to an aberrant 
elevation of miR-34a (Herbert et al. 2014). 
While miRNAs are the drivers of several key metabolic processes associated with diabetes, 
such as insulin secretion and gluconeogenesis, no research has yet conclusively interconnected 
arsenic, miRNAs, and T2D. However, the overlap between the miRNAs modulated in expression 




the effects of arsenic and its metabolites on the development of diabetes could be mechanistically 
explained, at least in part, by miRNAs and therefore warrants further investigation. 
1.6 Conclusions and next steps 
 Data from recent studies support an association between iAs exposure and diabetes. 
While the underlying molecular mechanisms remain poorly characterized, miRNAs have 
emerged as one compelling class of molecules that may serve as a mechanistic link.  Future 
studies must address several limitations and knowledge gaps, two of which we describe here. 
(1) Functional studies of arsenic effects. Published in vitro and in vivo studies on arsenic 
exposure vary widely in terms of the arsenic species used, the concentration applied, the 
duration of treatment, and the cell types / tissues interrogated for functional assessment. 
In order to gain a more coherent understanding of the adverse diabetogenic effects of iAs, 
it will be important to identify and standardize a range of physiologically relevant 
concentrations and exposure durations. Furthermore, it will be critical to expand the cell 
types analyzed to include those of particular relevance to T2D etiology (e.g., intact islets, 
hepatocytes, intestinal epithelial cells, skeletal muscle cells, etc). Finally, more in vivo 
studies, ideally across different strains of mice, are required in order to understand the 
effects of chronic iAs exposure in genetically diverse populations. 
 
(2) MiRNA profiling in response to iAs. Most miRNA expression studies in response to 
iAs exposure/treatment have been carried out with real time quantitative PCR (RT-qPCR) 
and/or microarray technology. The former is low-throughput and the latter suffers from 




miRNAs with very similar sequences. Although not without its own challenges, 
sequencing-based approaches have become the gold standard for miRNA profiling 
(Pritchard et al. 2012). It will be imperative in the future to apply sequencing technology 
to study the miRNA response to iAs exposure/treatment. 
Future studies should focus on identifying the miRNAs that are most reproducibly altered by 
iAs and determining through loss- and gain-of-function studies which if any of these miRNAs 
may mediate the adverse effects of iAs exposure. If specific miRNAs are identified as 
mechanistic links between iAs and metabolic defects, then they may represent attractive 





















Table 1.1: Reports in the literature of altered miRNA expression in various cell lines               




Concentration Duration Cells/ Tissue Author 









(Beezhold et al. 
2011) 
miR- 21, let-7, 130a, 103, 107, 132, 16, 
182, 193a-3p, 194, 196b, 19b, 200a, 215, 
221, 23b, 26a, 29b, 29c, 335, 365, 493, 151-
5p, 138, 301a, 96, 429, 10a, 524-3p, 487b, 
361-5p, 15b, 24, 30b, 425, 532-5p, let-7a, 
20b, 100, 106b, 148b, 17, 30d, 15a, 93, 
125b, 101, 92a, 1184, 10b, 145, 128, 362-
5p, 937, 140-3p, 20a, 25, 33a, 940, 886-3p, 
874, 28-5p, 181a, 339-3p, 29a, 30c, let-7f, 
let-7d, let-7g, 1287, 27a, 375, 31, 191 
Up 
Arsenite  20 µM  24 hrs 
HUVEC 
cells  
(Li et al. 2012)  
miR- 299-3p, 325, 200c, 622, 585, 934, 
183, 761, 892b, 122, 135a, 640, 549, 508-
5p, 638, 1249, 1299, 205, 1252, 548n, 198, 
617, 890, 542-5p 
Down 










(Sturchio et al. 
2014) 
miR-150, 181a, 142-5p  Down 144 hrs 
miR-34a  Up Arsenite 0.5 µM  24 hrs keratinocytes 
(Herbert et al. 
2014) 
miR-24, 29a, 30a, 210, 886-3p Up Arsenic 
trioxide 
2 µM 24 hrs 
Hep-G-2 
cells 
(Meng et al. 
2011) miR-744, 296-5p, 663, 675 Down 
miR- 215, 125b, 335, 193b, 126, 1, 125a-
5p, 19a, 16, 122, 218, 100, 146a, 10b, 143, 
150, let-7g, 193a-5p, 96, 183, 181b, 146b-
5p, 9, 21, 27a, 98, let-7d, 148a, 155, 7, 30c, 
363, 181d, 196a, 18a, 184, 29a, 200c, 10a, 
144, 203, let-7a, 140-5p, 132, 23b, 148b, 
124, 32, 128a, 20b, 214, let-7f, 133b, 17, 




2 µM  48 hrs NB4 cells 
(Ghaffari et al. 
2012) 
miR-34c-5p, 149, 212, 372 Down 
miR- 200a, 200b, 200c Down 
Sodium 
arsenite 






miR-22, 21, 34a, 205, 141, 1260, 720, 1280, 











(Gonzalez et al. 
2015) 




4 µM 24 hrs T24 cell line 
(Cao et al. 
2011) miR-19a Down 
In Vivo Studies 
(rno) miR-183, 872, 148b, 151, 126a, 192, 











(Ren et al. 
2011) 
(rno) miR-26a, 34c, 423, 702, 6321, 20a, 
425, 664-1, 125b-1, 19a, 339 
Down 
Human Population Studies 
miR-21, 221 
 
Up Arsenic  




(Kong et al. 
2012) 








(as measured in 
urine) 
 Cord blood  







CHAPTER 2: CIRCULATING MIRNAS ASSOCIATED WITH ARSENIC EXPOSURE 
 
2.1 Introduction 
Inorganic arsenic (iAs) is a common drinking water contaminant. Exposure to iAs 
through consumption of contaminated water is of concern for over 200 million people in 70 
countries, including the United States, Mexico, Bangladesh, or China (Stanton et al. 2015). 
These individuals are exposed to levels of iAs higher than the maximum limit of 10 µg As/L (10 
ppb) set by the US EPA and World Health Organization (Agency for Toxic Substances 2007). 
Though exposure to iAs in drinking water is the primary concern, additional exposures are 
associated with the consumption of foods grown in iAs-rich soils (Stanton et al. 2015). Because 
iAs is a group 1 human carcinogen (2004), the US EPA and the Agency for Toxic Substances 
and Disease Registry (ATSDR) rank arsenic (As) as first on the US Priority List of Hazardous 
Substances (Agency for Toxic Substances 2007). The association between exposure to iAs in 
drinking water and cancer, including cancer of the urinary bladder, kidney, skin, and liver has 
been firmly established (2004). More recent and growing evidence has linked iAs exposure also 
to non-cancer pathologies, for example cardiovascular disease (Tseng et al. 1996; Chiou et al. 
1997), hypertension (Chen et al. 1995; Rahman et al. 1999), and diabetes (Tseng 2007; Maull et 
al. 2012; Beck et al. 2017).  
Mexico is among the countries where environmental iAs exposure is of particular 




(Del Razo et al. 1990, 1993, 2002; Armienta et al. 2001). The contamination of drinking water 
supplies with iAs has been documented in 14 Mexican states: Zimapan, Durango, Coahuila, 
Zacatecas, Morelos, Aguascalientes, Chihuahua, Sonora, Puebla, Nuevo León, Jalisco, Oaxaca, 
Guanajuato and San Luis Potosí (Bundschuh et al. 2012).  An estimated 450,000 residents of 
these states use drinking water supplies, in which iAs concentrations exceed 50 μg As/L (Limón-
Pacheco et al. 2018). Adverse health effects associated with iAs exposure in these regions 
include skin lesions (Valenzuela et al. 2009), increased risk of cardiometabolic diseases (Mendez 
et al. 2016a), including diabetes mellitus (Del Razo et al. 2011), and neurological (Rosado et al. 
2007) and genotoxic effects (Méndez-Gómez et al. 2008).The present study used samples and 
data that were collected in Zimapán and in the Lagunera region, an area located on the border of 
the Durango and Coahuila states.  
The individual susceptibility to adverse effects of iAs exposures is determined by a 
variety of factors, most importantly by the efficiency of iAs metabolism (Jansen et al. 2016). 
Humans, as well as many animal species, metabolize iAs in a series of methylation reactions that 
are catalyzed by a single enzyme arsenic (+3 oxidation state) methyltransferase (AS3MT) to 
form monomethyl-As (MAs) and dimethyl-As (DMAs) metabolites, which are excreted 
primarily in the urine. The urinary profiles of As species have often been used in population 
studies to characterize both iAs exposure and the pattern of iAs metabolism. High proportions of 
urinary DMAs (%DMAs) and low proportions of iAs (%iAs) and MAs (%MAs) in the urine are 
generally considered indicators of efficient iAs metabolism, whereas low %DMAs or low 
DMAs/MAs ratio is thought to indicate an impairment in iAs methylation. Analysis of iAs and 
its metabolites in other biological specimens, e.g., blood, plasma, saliva, or exfoliated epithelial 




internal dose of As in iAs-exposed individuals (Bhowmick et al. 2014; Currier et al. 2014; Howe 
et al. 2016; Grau-Perez et al. 2017). While the role of iAs metabolism in the adverse effects of 
iAs exposure is well characterized, less is known about molecular factors that mark and/or 
underlie these effects.  
There has been a growing interest among researchers to identify sensitive, non-invasive 
molecular markers to aid in disease risk prediction. MicroRNAs (miRNAs) have emerged as 
potential early markers of disease risk, and in some instances, mediators of disease(Sethupathy 
2016). MiRNAs are small RNAs consisting of ~22 nucleotides, that regulate gene expression by 
binding to the 3’-untranslated regions of one or more target mRNAs (Bartel 2018).  They have 
emerged as important components of gene regulation that control a wide array of physiological 
and pathological processes, most notably cancer development (Iorio and Croce 2012), 
hypertension (Bátkai and Thum 2012), atherogenesis (Vickers and Remaley 2010), insulin 
resistance (Trajkovski et al. 2011b), and overt type 2 diabetes etiology (He et al. 2017). 
MiRNAs are also present and highly stable in many different extracellular fluids, 
including blood, urine, and saliva. Most miRNAs are fairly widespread in expression and so it is 
often difficult at best to discern the tissue-of-origin for specific miRNAs altered in circulation 
(Hung and Sethupathy 2017). However, some miRNAs tend to be robustly enriched in a few cell 
or tissue types; examples include miR-122 in liver, miR-206 in muscle, and miR-514a-3p in 
testis (Ludwig et al. 2016). If such miRNAs are present in circulation at aberrant levels then it 
could be indicative of dysregulation in specific tissues (De Guire et al. 2013). There is growing 
interest in the potential of circulating miRNAs to serve as early markers before overt disease 
manifestation, as well as prognostic indicators of disease course (Rager et al. 2014b). Several 




disease, including miR-29b in blood and saliva as a prognostic measure for oral squamous cell 
carcinoma, and 10b as a circulating biomarker of gliomas (Hayes et al. 2014).   
MiRNAs in tissues such as liver (Kurtz et al. 2015b) and adipose (Ying et al. 2017; Yao et 
al. 2018) have been shown to respond to various metabolic and environmental stimuli, including 
exposure to iAs (Schembri et al. 2009; Vrijens et al. 2015; Sollome et al. 2016). Notably, some 
of the miRNAs that were found to be altered by iAs exposure have also been found to play a role 
in etiology of various human diseases, e.g., cancer or diabetes. The goal of the present study was 
to identify circulating plasma miRNAs that are characteristic of chronic iAs exposure as the first 
step in determining the role of miRNA as potential mediators or markers of disease associated 
with exposure.  
2.2 Materials and Methods 
2.2.1 Study participants and sample collection.  
The present study used samples and data collected previously from participants in the 
Zimapán and Lagunera cohorts in Mexico (Del Razo et al. 2011). These cohorts were described 
in detail elsewhere (Del Razo et al. 2011). Briefly, the participants (males and females, ≥5 years 
old) were recruited among residents of the Zimapán and Lagunera regions who were exposed to 
iAs in drinking water. Only participants with two or more years of residency in the study areas 
were recruited. Excluded from the study were pregnant women and individuals who reported 
alcohol abuse or having a chronic or acute urinary tract disease or type I diabetes. All procedures 
included in this study were approved by Institutional Review Boards of Cinvestav-IPN, Mexico 
City, Mexico and University of North Carolina at Chapel Hill, North Carolina, USA. Each of the 




which plasma was prepared by centrifugation at 4oC. All participants also provided samples of 
water they typically used for drinking. In these cohorts, iAs exposure was associated with 
increased prevalence of diabetes (Del Razo et al. 2011). The present study used plasma samples 
from 109 randomly selected participants that were not diagnosed with diabetes or pre-diabetes. 
2.2.2 Analyses of As and As species in water and plasma 
The analysis of As in drinking water was described in detail in the original report on the 
Zimapán and Lagunera cohort (Del Razo et al. 2011). Plasma samples were analyzed in the 
Styblo lab at the University of North Carolina, Chapel Hill using hydride generation–
cryotrapping (HG-CT)-inductively coupled plasma-mass spectrometry (ICP-MS). This method, 
including sample preparation, limits of detection, coefficients of variation, and procedures used 
for quality assurance/control, have been described in detail in our previous reports (Matoušek et 
al. 2013; Grau-Pérez et al. 2017; Bommarito et al. 2018) Using HG-CT-ICP-MS, we measured 
concentrations of iAs, MAs, and DMAs in plasma. Total As (TAs) concentration was calculated 
as the sum of iAs, MAs, and DMAs. The percentages of TAs represented by iAs, MAs, and 
DMAs (%iAs, %MAs, and %DMAs) were used as markers of the efficiency of iAs metabolism. 
2.2.3 High throughput sequencing for miRNA profiling.  
Qiagen miRNeasy Serum/Plasma Kit (Qiagen, Venlo, Netherlands) was used to extract 
RNA from 50 µL aliquots of 109 fasting plasma samples. RNA concentrations ranged from 11 – 
140 ng/µL. A Nanodrop spectrophotometer was used to examine RNA concentrations and purity. 
We performed small RNA sequencing as described previously (Keith et al. 2018), using Illumina 




An alignment tool, miRquant 2.0 (Kanke et al. 2016), was used for adapter trimming, and 
alignment of reads to the hg19 version of the human genome using two different mapping tools 
(Bowtie and SHRiMP), before quantifying miRNAs and miRNA isoforms (termed isomiRs). We 
then performed normalization (reads per million mapped to miRNAs (RPMMMs)), and miRNAs 
with greater than 50 RPMMMs in at least one sample were included for further analysis. This 
threshold yielded a set of 596 detected miRNAs across all samples. MiRNAs with an average 
<25 RPMMM across all samples were removed which resulted in 362 robustly expressed 
miRNAs.  
Of the 109 samples sequenced, several showed signs of RNA degradation (Appendix 1, 
Supplementary Figure 1) and were excluded from the study. These samples were collected over 
10 years ago in remote regions of central and northern Mexico. At these locations, we could not 
use liquid nitrogen to snap-freeze the plasma samples before transport to Mexico City. Instead 
dry ice was used. Thus, the observed variances in mapping rates may be attributed to the 
degradation of RNA due to sample handling. Several other samples exhibited low numbers of 
mapped reads. Only samples with at least 1 million mapped reads to miRNAs (a total of 82 
samples) were used for further analysis.  
2.2.4 Statistical analysis.  
Variables were assessed using a Kolmogorov–Smirnov test for normality. All normalized 
sequencing reads (RPMMM) were then transformed with a Box-Cox transformation. (Package 
‘car’; RStudio Version 1.0.136). The association between plasma As levels and miRNA 
expression levels were evaluated in samples using a general linear regression model, in which 




dependent variable. Covariates potentially influencing miRNA expression levels such as age 
(continuous), sex (categorical), body mass index (BMI) (continuous), smoking status 
(categorical), and alcohol consumption status (categorical) were included in the regression 
model. Significant associations between miRNA expression and plasma As were classified as 
having a P-value < 0.05 and a false discovery rate (FDR) adjusted value (q-value) <0.15 using an 
analysis of covariance (ANCOVA) model. A significance cut-off of q< 0.15 was chosen based 
on previously published circulating miRNA literature (Permuth-Wey et al. 2015; Rizzo et al. 
2015; Narla et al. 2018). 
We computed adjusted R2 values (Ra
2) using simple linear regression models to estimate the 
explained variation of the model (i.e., R2 values were adjusted for the number of parameters in 
the model). 
2.3 Results 
2.3.1 Basic characteristics of the sub-cohort.  
The present study focused on analysis of 82 plasma samples that satisfied criteria for 
good quality RNA and for number of mapped miRNA reads. The basic demographic 
characteristics of the donors of these samples are shown in Table 2.1. The sub-cohort consists 
mostly of females (73.2%), aged 5-65 years. The majority of participants did not smoke or 
consume alcohol. BMI ranged from 14.5 to 50 Kg/m2; 62% of participants were obese or 
overweight with 28% having a BMI >30 kg/m2. These demographics are fairly consistent with 
those of the original cohort (N=258)13. The original cohort was also comprised of mostly women 





2.3.2 Concentrations of As in water and concentrations of As species in plasma. 
Of the 82 individuals, 61 (74.4%) drank water with As levels higher than 10 µg/L (ppb), 
ranging between 10.3 – 215.2 µg/L (Table 2.1). The concentrations of TAs in plasma (i.e., sum 
of iAs+MAs+DMAs) ranged from 0.221 – 9.669 ng/mL. Using a multiple regression analysis 
adjusted for the number of predictors or independent variables, we observed a modest but 
statistically significant correlation (Ra
2 = 0.146, P = 0.0002) between drinking water As and TAs 
in plasma (Fig 2.1D). Similar correlations were observed between water As and plasma MAs 
(Ra
2 = 0.185, P = 0.0001) or DMAs (Ra
2 = 0.184, P = 0.0001) (Figure 2.1B, C). We found no 
statistically significant correlation between As concentration in water at the concentration of iAs 
in plasma (Figure 2.1A). 
Table 2.1: Basic characteristics of the study participants. 




             Male 22 
             Female 60 
Smoking 
 
    Non-Smoker 78 
            Smokers 4 
Alcohol consumption 
 
            No 66 
            Yes 16 
Age (years) 34 (30) 
BMI (kg/m2) 27.09 (7.77) 
 
 IQR: The interquartile range is defined as the difference between the upper quartile (Q4; the 






Table 2.2: Concentrations of As in drinking water and of As species in fasting plasma1 
 
Arsenic Measure  N Median (IQR) Range 
Concentration of As in water (μg/L) 82 15 (38.05) 3.1 - 215.2 
Concentrations of As species  
82   
in plasma (ng As/mL) 
iAs  0.188 (0.115) 0.019 – 5.071 
MAs  0.221 (0.267) 0.047 – 2.844 
DMAs  0.347 (0.451) 0.083 – 3.155 
TAs  0.749 (0.845) 0.221 – 9.670 
Distribution of As species in plasma (% 
of TAs2) 
82   
iAs  25.20% (22.75) 3.9% - 52.5% 
MAs  28.23% (9.3683) 15.96% - 46.9% 
DMAs  45.07% (14.9) 18.135% - 69.8% 
 
1 Concentrations of As species in all water and plasma samples were above the limits of detection 







Figure 2.1: Correlations between log-transformed concentrations of As in drinking water (μg/L) 
and log-transformed plasma concentrations of iAs (A); MAs (B); DMAs (C); and TAs (D) 
(ng/mL).  
2.3.3 MiRNA sequencing data.  
The top 20 most abundant miRNAs (Figure 2.2) constitute nearly 80% of reads across all 
samples, with one miRNA (miR-486-5p) accounting for 35% of reads. This result is concordant 




al reported that in their samples miR-486-5p accounts for nearly 60% of the total number of 
reads, and 10 miRNAs constitute ~90% of all reads (Tong D 2016).  
 
Figure 2.2. Top 20 most abundant circulating miRNAs. 
2.3.4 MiRNAs associated with As species in plasma.  
MiRNAs associated with TAs and or with individual As species in plasma were 
identified using a linear mixed model, with adjustments for age, sex, BMI, smoking status and 
alcohol consumption. To conduct a comparative analysis, we used an unadjusted p-value (P) < 
0.05 for initial exploration, which revealed 40 shared miRNAs associated with MAs, DMAs, and 
TAs (Figure 2.3A). The inclusion of iAs in this analysis reduced the total number of shared 
miRNAs to 2 with P <0.05 (Figure 2.3B). MiRNAs associated with iAs can be distinguished 




each arsenical and suggesting they may be targeting different pathways and have different 
mechanisms contributing to their effects. A list of miRNAs associated with each arsenical can be 
found in (Appendix 1, Supplementary Table 2).  
 
Figure 2.3: MiRNAs associated with plasma arsenicals. The Venn diagrams show 40 shared 
miRNAs significantly (P < 0.05) associated MAs, DMAs, and TAs (A), and 2 miRNAs shared 
between iAs, MAs, and DMAs (B) before FDR adjustments.   
Next, P-values were adjusted using a FDR method. Using an adjusted value (q-value) 
threshold of 0.15, as has been used by other similar circulating miRNA studies  (Permuth-Wey et 
al. 2015; Rizzo et al. 2015; Narla et al. 2018), greatly reduced the number of miRNAs associated 
with each metabolite. Statistically significant associations were found only with 6 miRNAs, and 





Figure 2.4:  MiRNAs associated with plasma arsenicals after FDR adjustments. Significant 
associations (q <0.15) were found only between miRNAs and MAs.   
 
Table 2.3– MiRNAs associated with plasma MAs.  
MiRNA Partial Correlation 
Coefficient1 
P Value q Value 
hsa-miR-423-5p 0.356473 0.00231129 0.139448 
hsa-miR-142-5p -2 -0.39488 0.00138898 0.125703 
hsa-miR-423-5p +1 0.384065 0.00220734 0.139448 
hsa-miR-320c-1 0.363683 0.00116779 0.125703 
hsa-miR-320c-2 0.366302 0.00098734 0.125703 
hsa-miR-454-5p -0.39685 0.00099197 0.125703 
 
1Partial correlation coefficients were calculated with a linear regression model controlling for 





The exposure to iAs is of grave concern as it has been associated with a variety of 
diseases, including cancer (2004), cardiovascular disease (Chen et al. 2007; Mendez et al. 
2016a), and diabetes (Navas-Acien et al. 2006; Maull et al. 2012; Beck et al. 2017). The exact 
molecular mechanisms underlying these adverse health effects remain largely unknown, though 
many mechanisms have been proposed, e.g., oxidative stress (Sinha et al. 2013; Prakash et al. 
2016) , altered DNA repair (Muenyi et al. 2015) or DNA methylation and gene expression 
(Kessel et al.; Nesnow et al. 2002; Beck et al. 2017), or endocrine disruption9.  
Hou et al, 2011 proposed that exposure to chemicals in the environment could alter 
miRNAs abundance, and that this effect is associated with induction of oxidative stress or 
inflammation by these chemicals (Hou et al. 2011).  Sturchio et al then confirmed this by 
showing that short exposure (24 hrs) to a low concentration of iAs (2 µM) was enough to alter 
miRNA expression in Jurkat cells (Sturchio et al. 2014). Since then, several studies, including 
population studies, have observed altered miRNA expression in response to iAs exposure (Beck 
et al. 2017). For example, in humans, prenatal iAs exposure altered miRNA and gene expression 
in cord blood of newborns (Rager et al. 2014b). However, to our best knowledge, a large-scale 
analysis of the associations between iAs exposure and metabolism in adult populations with 
circulating miRNAs has not been previously published. The present study investigated the 
relationships between iAs exposure and circulating miRNA using data on iAs in drinking water 
and plasma samples collected in our previously established cohort in Mexico. The range of iAs 
concentrations in drinking water used by the participants in this cohort (3.1 to 215.2 μg/L) 
resembles those reported from other iAs-exposure areas, including several regions in the United 




contained As at levels ranging from 1 to 806 μg/L; 1436 wells had As levels above the  US EPA 
limit (Sanders et al. 2012).  
It has been recognized that measures of As in drinking water provide an incomplete 
picture of iAs exposure because additional exposures occur through diet, particularly 
consumption of crops grown in iAs-rich soils or foods cooked in water contaminated with iAs. 
To account for these sources of exposure, many published studies have measured As species in 
urine. It is not clear, however, whether urinary As levels and speciation reflect those in 
circulation or in target tissues. Bommarito and coworkers have recently compared the urinary 
and plasma concentrations of As species in the entire Zimapán/Lagunera cohort. They found 
statistically significant positive correlations between TAs, MAs and DMAs, but not iAs, in 
plasma and urine (Bommarito et al. 2018). Strong positive correlations were also found between 
As concentrations in drinking water and plasma TAs, MAs and DMAs. We were able to 
reproduce their findings in a subset of the cohort in the present study. Taken together, these data 
suggest that plasma TAs is a reliable indicator of iAs exposure, but the profiles of As species in 
urine differ from those in circulation. 
Using unadjusted p values, we found 2 plasma miRNAs (miRs-30c-1-5p, and -486-5p 
+1) to be associated with all As measures in plasma, including iAs, MAs, DMAs, and TAs, and a 
shared 40 miRNAs overlapping between MAs, DMAs and TAs. P-values were FDR adjusted to 
correct for multiple testing and a significance cut-off  of Q< 0.15 was chosen based on 
previously published circulating miRNA literature (Permuth-Wey et al. 2015; Rizzo et al. 2015; 
Narla et al. 2018). Using Q values narrowed the number of associated miRNAs to 6, and all were 
associated only with plasma MAs. MAs is an intermediary metabolite in the pathway for 




MAs (MAsIII) is the most toxic among the metabolites of iAs(Vahter and Concha 2001),(Styblo 
et al. 2000b). Notably, we have also shown that MAsIII inhibits insulin secretion in murine 
pancreatic islets (Douillet et al. 2013), and is also a potent inhibitor of insulin-dependent glucose 
uptake in adipocytes (Paul et al. 2007a) and insulin-stimulated glycogen synthesis in hepatocytes 
(Zhang et al. 2017). MAs in urine have been linked to adverse effects of iAs exposure in humans 
(Kuo et al. 2017). For example, a study by Melak and co-workers indicated that higher 
proportions of urinary As present in the form of MAs (%MAs) were associated with increased 
risk of bladder cancer among residents of northern Chile who were exposed to  iAs in drinking 
water (Melak et al. 2014). Similarly, higher urinary %MAs was risk factor cardiovascular disease 
in a prospective study in Bangladesh (Chen et al. 2013b). In contrast, lower %MAs was 
associated with a higher incidence of diabetes in the Strong Heart study (Kuo et al. 2015b). Thus, 
the urinary profiles of As species, MAs in particular, are indicators of disease risk associated 
with iAs exposure.  
Among the six miRNAs identified in this study to be significantly associated with plasma 
MAs, two were variants of canonical miRNAs, or isomiRs. Two of the six small RNAs identified 
in the present study have been previously recognized as being associated with diabetes or 
cardiovascular dysfunction, disorders that have been previously linked with iAs exposure (Maull 
et al. 2012; Mendez et al. 2016a). Our study revealed both miR-423 as well as an isomiR, 423-5p 
+1, as being significantly associated with plasma MAs. MiR-423-5p has been linked to type 2 
diabetes status in patients (Ortega et al. 2014) and contributed to explain variance in fasting 
glucose. This connection may be explained by the interaction of NFE2 and miR-423 to repress 
the FAM3A-ATP-Akt pathway, which promotes gluconeogenesis and lipid deposition in the 




pancreatic islets, and therefore a definitive connection with disease etiology cannot be made 
without further experimentation. Nabiałek et al. also detected an early rise in miR-423-5p in 
circulation of patients with acute myocardial infarction (Nabiałek et al. 2013), suggesting it may 
harbor diagnostic potential.  
In a study comparing the circulating miRNA profiles of individuals diagnosed with type 
1, type 2, or gestational diabetes in Brazil, miR-142-5p was found to be one of nine miRNAs in 
common with all three types (Collares et al. 2013). MiR-142 is also one of four miRNAs that can 
differentiate patients with childhood dilated cardiomyopathy from healthy subjects(Jiao et al. 
2018). Our study revealed an isomiR, miR-142-5p -2, to be significantly associated with plasma 
MAs. Finally, it has been shown that miR-454 exhibits altered expression in human cord blood 
from prenatal infants with maternal exposure to iAs (Rager et al. 2014b), and was observed to be 
downregulated in instances of diastolic dysfunction (Nair et al. 2013). These 3 miRNAs or 
isomiRs have been linked to cardiometabolic disease in the general population as well as to 
plasma MAs levels in the present study, which suggests that they are not specific to iAs 
exposure, but rather may serve as indicators of a disease risk in populations exposed to iAs.  
While the remaining two miRNAs (miR-320c-1, -320c-2), have not yet been implicated 
as circulating factors associated with either diabetes or iAs exposure, miR-320c has been shown 
to be one of several miRNAs upregulated in the urinary exosomes of patients with type II 






In conclusion, our results suggest that iAs exposure is associated with altered profiles of 
circulating miRNAs. We have identified 6 miRNAs in plasma that are associated with iAs 
exposure, specifically with plasma concentration of MAs, a toxic metabolite of iAs. Given the 
published data, four of these miRNAs (miRs-423-5p, 423-5p +1, -142-5p -2, and -454-5p) 
appear to be linked to risk of cardiometabolic diseases, while two other miRNAs (-320c-1, and -
320c-2) may be specific markers of iAs exposure. It is important to note that these 6 miRNAs 
were associated with MAs in plasma of healthy individuals. Future studies in large, well-
phenotyped populations exposed to iAs will help to further evaluate the sensitivity and 
specificity of these associations, which will be important for determining the utility of these 






CHAPTER 3: ARSENIC IS MORE POTENT THAN CADMIUM OR MANGANESE IN 
DISRUPTING THE INS-1 BETA CELL MICRORNA LANDSCAPE 
 
3.1  Introduction 
Diabetes mellitus, a complex metabolic disorder, is a growing epidemic currently 
affecting approximately 450 million individuals globally (2017). The International Diabetes 
Federation (IDF) predicts this number will more than double by the year 2025 (2017). There are 
three major types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes; but all 
three types are characterized by hyperglycemia and/or impaired glucose tolerance. Classical type 
2 diabetes (T2D) is often preceded by insulin resistance, but ultimately is due to pancreatic beta 
cell dysfunction. The causes of beta cell dysfunction are thought to be complex and multifactorial, 
with genetic susceptibility, obesity, exercise, and environmental exposures playing roles. Though 
beta cells make up the majority of the pancreatic islets, their capacity to proliferate is much 
lower than the other cell types (Bouwens and Rooman 2005). Furthermore, beta cells are 
extremely sensitive to environmental pollutants. In particular, exposures to estrogenic 
compounds, organophosphorus compounds, persistent organic pollutants and heavy metals have 
been shown to contribute to pancreatic beta cell dysfunction in both in vivo and in vitro 
laboratory experiments (Hectors et al. 2011; Makaji et al. 2011). Exposures to metal 
contaminants have been shown to increase the risk for developing dysglycemia (Fabricio et al. 
2016). Thus, more research is needed to understand and combat the effects of environmental 




Inorganic arsenic (iAs), a drinking water and food contaminant, is one of the most widely 
studied environmental toxicants linked to diabetes. iAs is naturally occurring and can be found in 
both pentavalent (iAsV) and trivalent (iAsIII) forms, though iAsIII is a more potent disruptor of 
glucose homeostasis. Several mechanisms have been proposed to explain this disruption 
including inhibition of insulin signaling (Paul et al. 2008), stimulation of gluconeogenesis (Liu et 
al. 2014b), and inhibition of glucose-stimulated insulin secretion (GSIS) (Douillet et al. 2013; 
Dover et al. 2017, 2018). Ingestion is the most common route of human exposure to iAs and 
once in the body it undergoes a series of reactions in which two methyl groups are added in 
succession forming methylarsenic (MAs) and dimethylarsenic (DMAs) species. Higher 
percentages of DMAs in urine have been associated with an increased incidence of T2D in 
human studies (Kuo et al. 2015a); however, in vitro laboratory studies showed that both MAs 
and DMAs, when in the trivalent state (MAsIII, DMAsIII), impair insulin secretion and 
mitochondrial metabolism in beta cells (Dover et al. 2017), and also impair insulin secretion in 
isolated murine pancreatic islets (Douillet et al. 2013).  
Cadmium (Cd) and Manganese (Mn) have also been studied in the context of T2D, albeit 
with contradicting results. Cd can accumulate in beta cells and cause dysfunction, which has 
been shown to increase insulin release in rats (Treviño et al. 2015) while being associated with 
lower insulin secretion in humans as observed in the Third National Health and Nutrition 
Examination Survey (NHANES III) cohort (Schwartz et al. 2003). Mn deficiency has been 
implicated in fasting hyperglycemia and T2D risk in epidemiological studies (Liu et al. 2016; Li 
et al. 2017). Though each metal may be influencing GSIS in a unique way, iAs, Cd and Mn have 
all been shown to impair beta cell mitochondrial function, which is an essential component of 




MicroRNAs (miRNA) are short, non-coding, single-stranded RNA molecules. They 
negatively regulate expression of target genes at the post-transcriptional level by binding to 3′ 
untranslated regions of target messenger RNA (mRNA). miRNAs are sensitive to environmental 
stimuli (Vrijens et al. 2015) which makes them excellent candidate biomarkers of exposure. 
Several circulating plasma miRNAs were recently found to be associated with the levels of MAs, 
a toxic metabolite of iAs, in the plasma of individuals exposed to arsenic through drinking water 
(Beck et al. 2018). 
Many miRNAs play important roles in the control of metabolic processes associated with 
impaired glucose homeostasis and T2D, such as gluconeogenesis in the liver (Yang et al. 2017), 
insulin secretion (Poy et al. 2004; Bagge et al. 2012; Jo et al. 2018), insulin sensitivity 
(Trajkovski et al. 2011b), and pancreatic beta cell survival (Belgardt et al. 2015).  
In this study, we examined the effects of iAs, MAsIII, Cd, and Mn on miRNA expression 
in an insulin secreting rat insulinoma cell line. This comparative analysis of miRNA profiles in 
beta cells in response to different contaminants, each of which have known associations with 
T2D, has never before been performed. Results of this study provide the first step toward the 
characterization of the potential roles of miRNAs in metal-induced beta cell dysfunction and 
potentially differentiate these from the mechanisms involved in classical T2D. 
3.2 Materials and methods 
3.2.1 Cell culture and treatments 
Rat insulinoma cells expressing human pro-insulin, INS-1 832/ 13 (Hohmeier et al. 
2000b), passage numbers 50–59, were cultured at 5% CO2, 37°C in RPMI 1640 medium (Gibco, 




glutamine (Gibco, Waltham, MA), 1mM sodium pyruvate (Gibco, Waltham, MA), 100 U/ml 
penicillin (Gibco, Waltham, MA), 100μg/ml streptomycin (Gibco, Waltham, MA), and 0.05mM 
β-mercaptoethanol (Sigma, St. Louis, MO).   
INS-1 832/13 cells were exposed to iAs (iAsIII; sodium arsenite, > 99% pure; Sigma-
Aldrich, St. Louis, MO), MAsIII (methylarsine oxide, > 98% pure), CdCl2 (100% Pure; Sigma 
Aldrich, St. Louis, MO), or MnCl2 (≥ 99% Pure; Sigma Aldrich, St. Louis, MO) for 24h prior to 
GSIS, cell viability testing, or RNA isolation. 
3.2.2 GSIS 
INS-1 832/13 cells were seeded at a density of 1,000,000 cells/well in 12-well tissue 
culture plate 24 hours prior to exposure. Cells were then treated with iAs, MAsIII, Cd, or Mn for 
24 hours. Following this 24-hour exposure, cells were placed in a secretion assay buffer (SAB) 
comprised of 114 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.16 mM MgSO4, 20 mM Hepes, 
2.5 mM CaCl2, 0.2% bovine serum albumin, 25.5 mM NaHCO3, and 0 mM glucose for 40 min. 
After 40 min in glucose-free medium, cells were incubated in SAB containing 2.5 mM glucose 
for 60 min and 16.7 mM glucose for 2 h. Metal exposures were maintained during this time by 
adding 1 µM iAs, 0.5 µM MAs, 5 µM Cd, or 25 µM Mn alongside each SAB incubation. 
Aliquots of media were collected for the 2.5 and 16.7mM glucose incubations and cells 
were lysed for protein analysis. The amount of insulin secreted from cells into the media was 






3.2.3 Cell Viability Assay  
INS-1 832/13 cells were seeded at a density of 100,000 cells/ well in a 96 well plate. 24 h 
after plating, arsenicals were added along with CellTox™ Green Dye using the express, no-step 
addition at dosing method for the CellTox™ Green Cytotoxicity Assay (Promega, Madison, WI). 
Fluorescence at 485Ex/520EM was measured at 24 h following addition of metals in a Synergy 
HT plate reader. Fluorescence indicates a loss of membrane integrity occurring as a function of 
cytotoxicity, and loss of cell membrane integrity has been linked to cell death.  
3.2.4 Pancreatic islets from mice exposed to iAs in vivo 
Pancreatic islets from a recently completed study were used in this experiment. All 
procedures involving mice were approved by the University of North Carolina Institutional 
Animal Care and Use Committee. Male and female C57BL/6J WT mice were obtained from 
Jackson Laboratories and let to acclimatize at the UNC Animal Facilities for one week. Mice 
were housed under controlled conditions with 12-h light/dark cycle at 22 ± 1 °C and 50 ± 10% 
relative humidity. Mice were randomly assigned treatment groups with 1-3 animals per group. 
Both male and female mice drank for 20 weeks (ad libitum) either deionized water or deionized 
water containing sodium arsenite (AsNaO2, ≥ 99% pure; Sigma-Aldrich, St. Louis, MO, USA) at 
final concentrations of 0.1 mg As/L (100 parts per billion). Water with sodium arsenite was 
prepared weekly to minimize oxidation of iAsIII to As
V. Mice were sacrificed by cervical 
dislocation and pancreatic islets were isolated using previously described procedures (Douillet et 
al. 2013). Briefly, the pancreas was infused in situ with collagenase P (1 mg/mL, Roche 
Diagnostics Corp., Indianapolis, IN) via the common bile duct. Pancreas was then removed and 




were purified by centrifugation in a gradient of Ficoll PM 400 (GE Healthcare, Uppsala, 
Sweden). The islets were stored at -80oC. 
3.2.5 Statistical analysis 
All data derived from INS-1 832/13 cells are presented as technical replicates from 3 or 
more biological replicates as specified in the figure legends. Boxplots represent the 25th 
(bottom), 50th (middle), and 75th (top) percentiles of the data. The protein normalized insulin 
values were analyzed using a Student’s t-test. Data are presented as ng insulin/ µg protein, mean 
± standard error of the mean (SEM) or as mean ± standard deviation (SD) as indicated; p values 
less than 0.05 are considered statistically significant.  
3.2.6 RNA isolation, Small RNA Sequencing, RNA Sequencing, and qPCR 
Following a 24-hour exposure in INS-1 cells or immediately after isolation of islets, total 
RNA was isolated using the Total RNA Purification kit (Norgen; Ontario, Canada). RNA 
concentrations were examined with a Nanodrop spectrophotometer, RNA yield and integrity 
were measured by Agilent 2100 Bioanalyzer (Santa Clara, CA).  
We performed small RNA sequencing as described previously (Beck et al. 2018), using 
Illumina HiSeq, which resulted in an average of 32 million reads per sample.  
RNA sequencing libraries were prepared using the Kapa mRNA Library Prep Kit (Kapa 
Biosystems). Paired end sequencing was performed on the Highseq4000 platform at the UNC 
High Throughput Sequencing Facility (University of North Carolina, Chapel Hill, NC).  
For RT-qPCR, one µg of total RNA was used for reverse transcription with the High 




for reverse transcription with the TaqMan microRNA Reverse Transcription kit (Life 
Technologies). MiRNA qPCR was performed using TaqMan Universal PCR Master Mix (Life 
Technologies) per the manufacturer’s protocol, on a Roche LightCycler 480 II PCR Detection 
System (Roche; Basel, Switzerland). Reactions were performed in triplicate using U6 as the 
normalizer.  
3.2.7 Bioinformatic Analyses 
For small RNA the alignment tool miRquant 2.048 was used for adapter trimming, and 
alignment of reads to the rn6 version of the rat genome using two different mapping programs 
(Bowtie and SHRiMP), before quantifying miRNAs and miRNA isoforms (termed isomiRs). On 
average, 80% of the trimmed reads mapped to the rat genome, of which ~50% corresponded to 
microRNA loci. (Appendix 1, Supplemental Table 3) The length distribution of mapped reads 
revealed a clear peak at the size range 21–24 nucleotides (Fig. 3.1), which matches the 
expectation for miRNAs. MiRNAs with greater than 25 reads per million mapped to miRNAs 
(RPMMM) in at least one sample were included for further analysis. This threshold yielded a set 
of 406 detected miRNAs across all samples. Differential expression analysis for miRNAs was 
performed using DESeq2.   
RNA-seq data were mapped to the rn6 genome with STAR, and transcripts were 
quantified with Salmon. Normalization and differential analysis was performed using DESeq2. 
Genes were classified as differentially expressed if they had a fold change ≥1.5 in either 





3.2.8 Functional Analysis of Differentially Expressed Genes 
Functional analyses were performed using Enrichr (http://amp.pharm.mssm.edu/Enrichr). 
Databases used for protein interactions include the CORUM database, a collection of 
experimentally verified mammalian protein complexes (Ruepp et al. 2008); the ChIP-x 
Enrichment Analysis (ChEA) database, a gene-set library with transcription factors labeling sets 
of putative target genes curated from published experiments (Lachmann et al. 2010); and a 
protein-protein interaction (PPI) network (Chen et al. 2012). The Kyoto Encyclopedia of Genes 
and Genomes (KEGG) was used to identify enriched biological pathways (Ogata et al.).  
 
Figure 3.1. Read length distribution from small RNA-seq in INS-1 832/13 cells after 24-hour 







3.3.1 Effects of metal exposure on insulin secretion and cell viability 
First, we examined the effects of 24-hour exposure to 1 µM iAs, 5 µM Cd, or 25 µM Mn 
on insulin secretion by maintaining INS-1 832/13 cells for 1 hour in low glucose containing 
medium followed by stimulating for 2 hours with high glucose medium. Metal exposure was 
maintained for the duration of the glucose stimulation. We found that exposure to each of the 
three metals significantly decreased insulin secretion in cells stimulated with 16.7 mM glucose 
(Fig. 3.2a); iAsIII by 61%, Cd by 68%, and Mn by 59%. To examine if the diminished GSIS was 
due to loss of cells we normalized the amount of secreted insulin for cellular protein. We also 
measured cell viability using CellTox™ Green. Here, cells treated with digitonin were used as 
positive controls. The 24-hour exposure to iAs, or Cd had no effects on cell viability. Cells 
















Figure 3.2. Glucose stimulated insulin secretion by INS-1 832/13 cells (a) and cell viability (b) 
after 24-hour exposure to 1 µM iAs, 5 µM Cd, or 25 µM Mn. Data are represented as mean of 6-
8 technical replicates + SE for 3 or more biological replicates. **p < 0.01; ***p < 0.001 
treatment versus control high glucose stimulation or treatment versus control fluorescence.  
3.3.2 Identification of robustly expressed miRNAs significantly dysregulated by metal 
exposure 
To identify metal-responsive miRNAs, we performed high throughput sequencing on 
untreated cells as well as those exposed to iAs, Cd, and Mn. Reads between 18-24 nucleotides in 
length comprised 58-62% of mapped reads across samples (Fig. 3.1). Principle Component 
Analysis (PCA) based on the 50 most variably expressed miRNAs revealed highly distinct 
miRNA profiles among the treatment groups (Fig. 3.3a). PC loading analysis revealed the most 
variable miRNAs among the different conditions (Table 3.1). Sequencing data was further 
analyzed using DESeq2. Setting a fold change threshold of >=1.5 in either direction, and an 
adjusted p-value <0.05, we found that 12 miRNAs are significantly altered by one or more metal 




resulting in the dysregulation of 9 miRNAs, as compared to 1 and 2 miRNAs altered by Cd and 
Mn exposure, respectively (Fig. 3.3b, Table 3.2).  
Two miRNAs, miRs-146a and 708, were selected for validation by quantitative RT-PCR 
(qRT-PCR) based on their established roles in beta cell health (Roggli et al. 2010) and function 
(Rodríguez-Comas et al. 2017). This analysis revealed an almost two-fold increase in miR-146a 
upon exposure to iAsIII whereas Mn had the opposite effect, and no change was seen with Cd 
exposure. Also, exposure to iAsIII caused a nearly two-fold decrease in the expression of miR-
708, while Cd and Mn exposure both had non-significant effects. These data confirm the results 
obtained from high-throughput sequencing (Fig. 3.3c). 
To obtain preliminary data on miR-146a expression after in vivo exposure to iAs, we 
performed small RNA-seq on islets previously isolated and archived as part of another study in 
which mice were exposed to 100 ppb iAs in drinking water. Islets from only a total of N=6 males 
and N=3 females across both treated and untreated conditions were available to us. The results 
suggest that iAs effects on miRNA-146a expression may be sex-specific, because we observed 
an upregulation of miR-146a only in the female mice (Appendix 1, Supplementary Fig 2). 
However, we stress that this particular finding is very preliminary given the low sample size; 
therefore, well-powered and rigorously-controlled in vivo studies with both sexes included are 
































Exposure miRNA Fold Change P-value P-adj 
iAs 
rno-mir-708-5p 1.5566526 6.71E-13 2.24E-10 
rno-mir-146a-5p 1.7613383 1.98E-12 4.97E-10 
rno-mir-29b-1-5p_-_5 1.7117298 2.20E-10 2.45E-08 
rno-mir-369-3p 1.5683211 3.12E-06 0.000174 
rno-mir-541-5p -1.6156638 3.48E-10 3.49E-08 
rno-mir-409a-3p_-_1 -1.8185392 1.20E-09 1.09E-07 
rno-mir-410-3p -1.7233563 6.84E-09 5.27E-07 
rno-mir-409a-3p_-_2 -1.5879385 7.62E-06 0.000333 
rno-mir-134-5p -1.5890461 8.97E-06 0.000374 
Cd rno-mir-195-3p -1.5995832 2.56E-08 5.14E-06 
Mn 
rno-mir-582-3p_-_1 -1.5280725 3.04E-11 1.54E-08 






Figure 3.3. (a) PCA plot of the top 50 most variable miRNAs across all samples and (b) volcano 
plot of miRNA expression changes after exposure to iAsIII, Cd, or Mn. Vertical lines represent a 
fold change of +/- 1.5, and the horizontal line is an adjusted p-value of 0.05; N=3 per treatment 
group (c) RT-qPCR validation of sequencing results for two robustly expressed miRNAs altered 
by metal exposure, miR-146a and miR-708.  Data are represented as mean of technical replicates 
(N=12 for each exposure) + SE for 3 or more biological replicates. *p <0.05; **p < 0.01; ***p < 






3.3.3 Upregulation of miR-146a is iAs-specific 
Since we found that iAs is the greatest disruptor of miRNA expression patterns, we 
focused our attention on iAs and one of its metabolites, MAsIII. First, we demonstrated a dose-
dependent suppression of GSIS by iAs (Fig. 3.4a), concomitant with a dose-dependent increase 
in miR-146a (Fig. 4b), as determined by RT-qPCR. These data indicate that miR-146a is 
inversely correlated with GSIS during iAs exposure. Next, we tested the effect of MAsIII. 
Although 0.5 uM MAsIII exerted an effect on GSIS similar to that of 1 uM iAs, it had no effect 
at all on miR-146a levels (Fig 3.4c, d). These data suggest that miR-146a is sensitive only to iAs 








Figure 3.4. GSIS (a) and miR-146a (b) expression (as determined by RT-qPCR) after 24-hour 
exposure to 0.5 or 1 µM iAs (miR-146a, 0 µM iAs N=27, 0.5 µM iAs N=15, 1 µM iAs N=22). 
Also, GSIS (c) and miR-146a (d) expression after 24-hour exposure to 1 µM iAs or 0.5 µM MAs 
(miR-146a, 0 µM iAs N=12, 0.5 µM iAs N=9, 1 µM iAs N=12). Data are represented as mean of 
technical replicates + SE for 3 or more biological replicates.     *p < 0.05; **p < 0.01; ***p < 
0.001 treatment versus control high glucose stimulation or treatment versus control relative 





3.3.4 Genes involved in beta cell function are significantly suppressed by iAs exposure, 
and several are validated targets of miR-146a-5p 
We next sought to investigate the effect of iAs on the gene expression landscape. We 
profiled genes by RNA-seq in INS-1 832/13 untreated cells (control) and in cells exposed to iAs 
for 24 hours. After DESeq2 analysis, we found 1288 significantly altered genes (610 genes 
downregulated and 678 upregulated; fold-change > 1.5 and adjusted p < 0.05) in exposed cells 
(Fig 5). Using the Enrichr analysis of the ChEA, PPI and CORUM databases, we found that 
upregulated genes are significantly over-represented in the Nfkb signaling pathway (Fig. 3.6). 
Increased Nfkb activity is consistent with the elevation in miR-146a expression (Taganov et al. 
2006). These data are indicative of a change in the Nfkb/miR-146 axis in response to iAs.  
To uncover candidate miR-146a targets that are affected by iAs exposure, we focused on 
down-regulated genes, since miRNAs are negative regulators of gene expression. Using the 
Enrichr tool, we found that the cAMP and Wnt pathways (Yajima et al. 1999; Abiola et al. 
2009), both of which are known to promote GSIS in beta cells, are enriched among down-
regulated genes (KEGG; adjusted p=0.068 and 0.069, respectively). Moreover, downregulated 
genes are also significantly enriched in the regulatory networks of ISL1 and FOXO1 (ChEA; 
adjusted p=0.000046 and 0.05, respectively), two transcription factors known to be important for 
controlling beta cell identity and function (Kitamura et al. 2005; Ediger et al. 2014). Lastly, we 
observed from the miRTarBase resource that several down-regulated genes are likely direct 
targets of miR-146a, most notably, Ca2+/calmodulin-dependent protein kinase IIα (Camk2a), an 






Figure 3.5. (a) A heatmap of Euclidean distance between samples based on DESeq2 normalized 
gene expression. (b) Volcano plot displaying genes altered by 24-hr iAs exposure. The vertical 
lines represent a fold change of +/- 1.5, and the horizontal line shows adjusted p=0.05. Control, 
N = 5; iAs, N=4. 
 
 
Figure 3.6. (a) Results of pathway enrichment analysis for upregulated genes (n=678) using the 
CORUM database. (b) Results of ChIP-X enrichment analysis for upregulated genes. (c) Results 
of protein-protein interaction enrichment analysis for upregulated genes. Dashed vertical line 





Exposure to iAs and other metals have been associated with an increased risk for the 
development of T2D and impaired pancreatic beta cell function. However, the genetic and 
molecular mechanisms underlying this risk remain unresolved. In this work, we have carried out 
the first step to explore this area. Specifically, we have performed a comparative assessment 
across different metals on GSIS and miRNA profiles, identified the most significantly 
dysregulated miRNAs in response to iAs exposure, and performed comprehensive gene 
expression profiling to uncover regulatory pathways that may contribute to iAs-associated 
defects. 
Several studies have reported that exposure to heavy metals might adversely affect 
pancreatic islet function and lead to the development of T2D. A 2012 study observed an 
inhibition of GSIS in a murine pancreatic beta cell line (MIN6) exposed to 1 µM Cd for 48 hours 
(El Muayed et al. 2012). Chang et al report significant cytotoxicity and impaired insulin 
secretion in rat RIN-m5F cells after 24-hour exposure to 3 or 5 µM Cd, respectively (Chang et al. 
2013). Similarly, previous research from our lab using the INS-1 832/13 rat insulinoma cell line 
observed an inhibition of GSIS after only 24 hours of exposure to 5 µM Cd (Dover et al. 2018) 
suggesting the effects of Cd on beta cell function may be cell-type dependent.  
Manganese is a well characterized essential trace metal. Mn serves as a cofactor for many 
reactions involved in the maintenance of glucose homeostasis, including reactions of insulin 
synthesis, and secretion (Korc 1983; Baly et al. 1984). As such, Mn deficiency has been 
implicated in diabetes development, potentially through an altered metabolism of the metal. 




of plasma manganese are associated with diabetes (Shan et al. 2016). An in vitro study by Dover 
et al demonstrated that exposures to 12.5 µM Mn for 24 hours in INS-1 cells causes an inhibition 
of the mitochondrial oxygen consumption rate as well as inhibition of GSIS (Dover et al. 2018).  
Numerous cross-sectional and prospective epidemiological studies from Taiwan, 
Bangladesh, Mexico, the U.S. and other areas have shown that chronic exposure to iAs is 
associated with diabetes (Maull et al. 2012; Wang et al. 2014b; Sung et al. 2015). Interestingly, 
human exposure to iAsIII is thought to cause an impairment of pancreatic beta cell function 
rather than insulin resistance (Del Razo et al. 2011; Gribble et al. 2012; Rhee et al. 2013). In 
vitro studies have expounded on this by showing that 24-hour exposure to non-cytotoxic 
concentrations of iAsIII results in an impairment of GSIS in INS-1 cells without affecting cell 
viability (Dover et al. 2017). Whole pancreatic islets exposed to iAsIII also exhibit impaired 
GSIS yet no detrimental effects on insulin content of the islets or islet viability were observed 
(Douillet et al. 2013).  Our current study confirms the impairment of GSIS after iAsIII exposure, 
and offers insight into potential transcriptional mechanisms leading to dysregulated GSIS.  
In our current study, iAs, Cd, and Mn exerted significant and comparable negative effects 
on GSIS. However, relative to iAs, Cd and Mn led to only modest effects on the miRNA 
landscape, which could suggest that these metals perturb GSIS through different molecular 
mechanisms. Published literature identified a role for miR-195 in pancreatic development in 
mice. Downregulation of miR-195 in our study could suggest a decreased regeneration ability in 
beta cells exposed to Cd. Mn exposure led to a downregulation of miR-582, whose target genes 
are greatly enriched in the Wnt signaling pathway (Fang et al. 2015). Activation of Wnt/β-
catenin signaling partially mediates the upregulation of glucose transporters in the cell membrane 




downregulation of miR-582 could suggest a compensatory mechanism by which the cell is 
attempting to increase Wnt signaling, and thus increase glucose uptake. Lastly, miR-125b was 
upregulated in response to Mn. A study by Bloomston et al shows miR-125b to be one of 7 
miRNAs overexpressed in chronic pancreatitis which could mean that a long-term exposure to 
Mn may be carcinogenic (Bloomston et al. 2007).  
A previous study of beta cell function and inflammation identified miR-146a as an 
important player in cytokine-mediated beta cell failure in MIN6 cells (Roggli et al. 2010). Newer 
studies using mouse models have confirmed the role of miR-146a as an important regulator of 
inflammatory cytokines (Bhatt et al. 2016; Chen et al. 2017). A recent meta-analysis of 12 
published studies found an association between T2D susceptibility and a downregulation of miR-
146a (Alipoor et al. 2017). Notably, iAs exposure has been established to increase inflammation 
and oxidative damage within the pancreas. Interestingly, while exposure to MAs did affect GSIS, 
it did not elicit the same upregulation of miR-146a, which may suggest that iAs and MAs act on 
different targets to affect insulin secretion. The upregulation of miR-146a in INS-1 cells may 
also represent a compensatory mechanism to protect against the inflammatory effects of iAs 
exposure. Our findings support the connections identified between miR-146a, iAs exposure, and 
oxidative stress that are worth investigating further. 
Camk2a is one of the main effector enzymes involved in calcium signaling, a critical 
mechanism regulating GSIS in beta cells (Dadi et al. 2014). It also serves as a mediator of the 
inflammatory response to oxidative stress (Waldsee et al. 2014; Zhang 2017; Zhong and Huang 
2017). Moreover, we and others have previously linked iAs exposure to decreased calcium influx 
and ultimately impaired GSIS (Díaz-Villaseñor et al. 2008; Huang et al. 2019). Several 




3’ UTR of the Camk2a gene (Chi et al. 2009; Leung et al. 2011; Schug et al. 2013). Overall, our 
findings suggest that iAs-induced suppression of GSIS could be explained in part by the 
inhibition of Camk2a and that this inhibition may be mediated by miR-146a. Future studies 
should focus on further functional characterization of Camk2a to determine whether its 
suppression contributes to reduced GSIS in the context of iAs exposure. 
3.5 Limitations 
In the present study, we used the INS-1 832/13 cell line, which has been widely used in 
studies examining insulin secretion and the underlying mechanisms (Hohmeier et al. 2000a; Park 
et al. 2007; Skelin et al. 2010; Lorenz et al. 2013; Dover et al. 2017; Jo et al. 2018). In our 
studies, inhibition of glucose-stimulated secretion in this cell line after in vitro exposure to iAs 
and its metabolites (Dover et al. 2017) was consistent with beta-cell dysfunction reported in 
epidemiologic studies carried out in populations exposed to iAs (Del Razo et al. 2011; Mendez et 
al. 2016b). Still, translatability of our current findings to in vivo conditions remains uncertain.  
Results of our pilot in vivo experiment suggest that miR-146a is also overexpressed in mouse 
pancreatic islets in response to in vivo iAs exposure, although this effect may be sex-specific. 
Our previous published studies show that susceptibility to the diabetogenic effects of iAs 
exposure differ between male and female mice (Huang et al. 2016, 2018; Douillet et al. 2017). 
Future studies should further elucidate the potential role of miR-146a, and other miRNAs, in 






The main findings in this work are four-fold: (1) the definition of metal-specific miRNA 
profiles; (2) the determination that iAs influences miRNA expression patterns much more 
robustly than Cd or Mn; and (3) the identification of miR-146a-5p as the most upregulated 
miRNA upon iAs treatment, and (4) the involvement of genes down-regulated by iAs in beta cell 
function, including Camk2a, a predicted target of miR-146a. Both miR-146a and Camk2a have 
been associated with insulin secretion, and therefore merit further functional investigation. To 
our knowledge, this study is the first to identify and report the potential relevance of the 
relationship between miR-146a-5p, Camk2a, and Nfkb signaling in the context of iAs-induced 








CHAPTER 4: MAPPING THE TRANSCRIPTIONAL LANDSCAPE OF ARSENIC-
EXPOSED PANCREATIC BETA CELLS 
 
4.1 Introduction 
 The genome is regulated through a wide range of mechanisms that act synchronously to 
induce or repress the expression of a gene. While studies like RNA-seq can provide insight to 
changes in gene expression, the transcriptional mechanisms that underlie these changes remain 
unknown. These mechanisms can include structural and chemical changes to the genetic 
material, as well as the binding of proteins to specific DNA elements to regulate transcription to 
RNA. While researchers can try to identify these mechanisms by studying the promoter regions 
of the most differentially expressed genes according to RNA-seq, recent evidence suggests that 
enhancers are more important than promoters for defining the gene expression program of a cell 
(Karnuta and Scacheri 2018; Rickels and Shilatifard 2018). Enhancers are a class of cis-
regulatory elements that promote gene expression and often are essential for eliciting the 
complex gene expression patterns. Enhancers typically span a few hundred base pairs (bp) and 
are composed of clusters of transcription factor binding sites (motifs) to which various trans-
activating and repressive factors can bind in a sequence-specific manner. They can be located in 
intergenic regions, introns and exons, anywhere from tens to hundreds of kilobases from their 
target genes (Kleinjan and van Heyningen 2005; Shlyueva et al. 2014; Karnuta and Scacheri 




Historically, the study of enhancers has been particularly challenging due to their many 
complexities. Enhancers are positioned throughout the entire genome and while they are often 
found upstream or downstream of a gene, they can also be situated within introns which makes 
their location relative to a target gene highly variable (Kleinjan and van Heyningen 2005). In 
addition, enhancers do not always act on the closest promoter but can actually regulate one or 
more genes located further along a chromosome (Pennacchio et al. 2013). As technology has 
advanced, many methods have been developed to overcome these challenges.  
There are multiple sequencing techniques to map enhancers, often by examining regions 
of open chromatin, such as DNase-seq or ATAC-seq (Dorschner et al. 2004; Buenrostro et al. 
2013). Over the last decade, studies have shown that active enhancer regions in the genome are 
transcribed into enhancer RNAs (eRNAs) (De Santa et al. 2010; Kim et al. 2010), which tend to 
be unstable and go undetected in traditional sequencing methodologies. Both proximal and distal 
regulatory elements are associated with RNA polymerase initiation (Kim et al. 2010; Core et al. 
2014; Andersson et al. 2015; Mikhaylichenko et al. 2018; Henriques et al. 2018). The 
development of nascent transcription (run-on) assays coupled with high throughput sequencing 
has allowed for the identification of enhancers and other regulatory elements by mapping the 
genome-wide locations of RNA polymerase activity (Core et al. 2008; Churchman and 
Weissman 2011; Kwak et al. 2013; Scruggs and Adelman 2015).  
 Here, I employ chromatin run-on sequencing (ChRO-seq) to identify genome-wide active 
promoters, active enhancers, and actively transcribed genes in INS-1 832/13 rat insulinoma cells 
with or without arsenic treatment. Previous run-on assays such as global run-on sequencing 
(GRO-seq) and precision run-on sequencing (PRO-seq) required cellular nuclear isolation, which 




mitigates these issues by optimizing a run-on reaction using chromatin fractions that contain an 
enzymatically active RNA polymerase (Chu et al. 2017). ChRO-seq allows me to characterize 
the transcriptional landscape of INS-1 832/13 cells for the first time and to examine the effects of 
arsenic exposure on regulatory elements that may drive cellular responses to arsenic and 
contribute to inhibition of glucose stimulated insulin secretion (GSIS) as a potential mechanism 
of arsenic-associated diabetes. 
Arsenic is a naturally occurring metalloid associated with numerous adverse health 
outcomes, including diabetes (Chapter 1). Arsenite (iAs) is the trivalent form of inorganic 
arsenic as it commonly exists in food and water and methylarsonite (MAs) is a trivalent 
metabolite of iAs. Both iAs and MAs have been shown to disrupt insulin secretion in INS-1 
832/13 cells at non-cytotoxic concentrations (Chapter 3), but the exact mechanism behind this 
disruption remains unknown. In a pilot study, I performed ChRO-seq on INS-1 cells treated with 
iAs (N=2), MAs, (N=2) or untreated “control” cells (N=2). 
Analysis of these data revealed that the genome-wide profile of transcriptional regulatory 
element (TRE) activity is sufficient to differentiate arsenic-exposed cells from unexposed cells, 
but were also able to stratify cells exposed to iAs from MAs-exposed samples. ChRO-seq 
analysis revealed that more TREs are significantly altered by MAs exposure than by iAs (iAs: 9 
up, 80 down; MAs: 312 up, 335 down). Exposure to both iAs and MAs reduced the activity of 
several TREs enriched in binding motifs for transcription factors associated with insulin 
transcription, content, and secretion. Both exposures resulted in reduced activity of TREs 
enriched in binding motifs for Pdx1, a TF that is critical for establishing and maintaining β-cell 
identity. These altered TREs may represent an additional, important mechanistic link between 





4.2 Materials and Methods 
4.2.1 Cell Culture 
Rat insulinoma cells expressing human pro-insulin, INS-1 832/ 13 (Hohmeier et al. 
2000b), passage numbers 50–59, were cultured at 5% CO2, 37°C in RPMI 1640 medium (Gibco, 
Waltham, MA) supplemented with 10% FBS , 10mM HEPES (Gibco, Waltham, MA), 2mM L-
glutamine (Gibco, Waltham, MA), 1mM sodium pyruvate (Gibco, Waltham, MA), 100 U/ml 
penicillin (Gibco, Waltham, MA), 100μg/ml streptomycin (Gibco, Waltham, MA), and 0.05mM 
β-mercaptoethanol (Sigma, St. Louis, MO).   
INS-1 832/13 cells were exposed to 1 µM iAs (iAsIII; sodium arsenite, > 99% pure; 
Sigma-Aldrich, St. Louis, MO), or 0.5 µM MAsIII (methylarsine oxide, > 98% pure) for 24h 
prior to GSIS, cell viability testing, or RNA isolation. 
4.2.2 Cell Viability Assay 
INS-1 832/13 cells were seeded at a density of 100,000 cells/ well in a 96 well plate. 24 h 
after plating, arsenicals were added along with CellTox™ Green Dye using the express, no-step 
addition at dosing method for the CellTox™ Green Cytotoxicity Assay (Promega, Madison, WI). 
Fluorescence at 485Ex/520EM was measured at 24 h following addition of metals in a Synergy 
HT plate reader. Fluorescence indicates a loss of membrane integrity occurring as a function of 






INS-1 832/13 cells were seeded at a density of 1,000,000 cells/well in 12-well tissue 
culture plate 24 hours prior to exposure. Cells were then treated with iAs or MAs for 24 hours. 
Following this 24-hour exposure, cells were placed in a secretion assay buffer (SAB) comprised 
of 114 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.16 mM MgSO4, 20 mM Hepes, 2.5 mM 
CaCl2, 0.2% bovine serum albumin, 25.5 mM NaHCO3, and 0 mM glucose for 40 min. After 40 
min in glucose-free medium, cells were incubated in SAB containing 2.5 mM glucose for 60 min 
and 16.7 mM glucose for 2 h. Exposures were maintained during this time by adding 1 µM iAs 
or 0.5 µM MAs alongside each SAB incubation. 
Aliquots of media were collected for the 2.5 and 16.7mM glucose incubations and cells 
were lysed for protein analysis. The amount of insulin secreted from cells into the media was 
determined using a Rat/Mouse Insulin ELISA kit (Crystal Chem) and normalized for cellular 
protein. 
4.2.4 Chromatin run-on and sequencing 
ChRO-seq was performed as previous described (Chu et al., 2018; Mahat et al., 2016) 
with minor modifications. Chromatin was isolated from frozen INS-1 832/13 cell pellets in 1 mL 
1X NUN buffer (20 mM HEPES, 7.5 mM MgCl2, 0.2 mM EDTA, 0.3 M NaCl, 1M urea, 1% 
NP-40, 1 mM DTT, 20 units/mL SUPERase In RNase Inhibitor (Thermo Fisher Scientific, 
Waltham, MA, AM2694), 1X Protease Inhibitor Cocktail (Roche, 11873580001)). Samples were 
vortexed for 1 minute, an additional 500 L of 1x NUN buffer was added to each sample, and 
the samples were vortexed for an additional minute. Samples were incubated in an Eppendorf 




before centrifugation at 12,500 x g for 30 minutes at 4C. Each sample was washed with 1 mL 
50 mM Tris-HCl (pH 7.5) supplemented with 20 units/mL SUPERase In RNase Inhibitor and 
centrifuged at 10,000 x g for 5 minutes at 4C. This wash step was repeated twice and samples 
were stored in 50 L of chromatin storage buffer (50 mM Tris-HCl pH 8.0, 25% glycerol, 5 mM 
magnesium acetate, 0.1 mM EDTA, 5 mM DTT, and 40 units/mL SUPERase In RNase 
Inhibitor). Samples were loaded into a Bioruptor (Diagenode, Denville, NJ) and sonicated on the 
high power setting for a cycle time of 10 minutes, consisting of 10 cycles of 30 seconds on and 
30 seconds off. Sonication was repeated as necessary to solubilize the chromatin and samples 
were stored at-80C.  
Following chromatin isolation, 50 L of chromatin was mixed with 50 µL 2X run-on 
reaction mix (10 mM Tris-HCl pH 8.0, 5 mM MgCl2, 1 mM DTT, 300 mM KCl, 400 M ATP, 
0.8 M CTP, 400 M GTP, 400 M UTP, 40 M Biotin-11-CTP (Perkin Elmer, Waltham, MA, 
NEL542001EA), 100 ng yeast tRNA (VWR, Radnor, PA, 80054-306), 0.8 units/L SUPERase 
In RNase Inhibitor, 1% sarkosyl). The run-on reaction was performed at 37C for 5 minutes and 
stopped by adding 500 L Trizol LS (Thermo Fisher Scientific, 10296-010) to the reaction. RNA 
samples were precipitated and resuspended in diethylpyrocarbonate (DEPC) treated water, heat 
treated at 65C for 40 seconds, and digested on ice with 0.2N NaOH for 4 minutes.  
Nascent RNA was purified with streptavidin beads (New England Biolabs (NEB), 
Ipswich, MA, S1421S) as previously described (Chu et al., 2018; Mahat et al., 2016). RNA was 
purified from beads using Trizol (Thermo Fisher Scientific, 15596-026) and 3’ adaptor ligation 
was performed with T4 RNA Ligase 1 (NEB, M0204S). Streptavidin bead binding was 
performed again following by 5’ decapping with RNA 5’ pyrophosphohydrolase (RppH, NEB 




(PNK, NEB M0201S) and 5’ adaptor ligation was performed with T4 RNA Ligase 1. The 5’ 
adaptor contained a 6-nucleotide unique molecular identifier (UMI) to allow for bioinformatic 
detection and elimination of PCR duplicates. Streptavidin bead binding was performed again 
followed by reverse transcription using SuperScript IV Reverse Transcriptase (Thermo Fisher 
Scientific, 18090010). cDNA was amplified by PCR using the Q5 High-Fidelity DNA 
Polymerase (NEB, M0491S) to generate ChRO-seq libraries. Libraries were sequenced at the 
Biotechnology Research Center at Cornell University on the NextSeq500 (Illumina, San Diego, 
CA). 
4.2.5 RNA Sequencing 
Total RNA was isolated using the Total RNA Purification Kit (Norgen Biotek) per 
manufacturer’s instructions. RNA purity was quantified with the Nanodrop 2000 (Thermo Fisher 
Scientific, Waltham, MA) or Nanodrop One and RNA integrity was quantified with the Agilent 
4200 Tapestation (Agilent Technologies, Santa Clara, CA) or Agilent BioAnalyzer. Libraries 
were prepared using the TruSeq Stranded mRNA Library Prep Kit (Illumina), the KAPA 
Stranded mRNA-Seq Kit (KAPA Biosystems, Wilmington, MA), or the NEBNext Ultra II 
Directional Library Prep Kit (New England Biolabs, Ipswich, MA). Sequencing was performed 
at the Biotechnology Research Center at Cornell University on theNextSeq500 (Illumina). 
4.2.6 ChRO-seq read mapping  
Read quality was assessed using FastQC.Adapters were trimmed from the 3’ ends of 
reads using cutadapt 1.16 (Martin 2011) with a 10% error rate. Each read contained a 6 bp UMI 




lite 0.20.2 (Schmieder and Edwards 2011). The processed reads were mapped to the rn6 genome 
modified with the addition of a single copy of the rat Pol I ribosomal RNA complete repeating 
unit (GenBank NR_046246.1) using BWA 0.7.13 (Li and Durbin 2010). Each read was 
represented by a single base at the 5’ end of the read, corresponding to the 5’ end of the nascent 
RNA. Data was converted to bigwig format using bedtools 2.27.1 (Quinlan and Hall 2010) and 
UCSC bedGraphToBigWig v4 (Kent et al. 2010) for visualization and identification of TREs.  
4.2.7 TRE identification 
To identify TREs across all samples, bigwig files of the same strand from all samples 
(Control, iAs, and MAs) were merged, and this merged dataset was used to call TREs. TREs 
from all samples were identified using dREG (Danko et al. 2015; Wang et al. 2019). Read counts 
were quantified within each TRE locus using the R package bigWig 
(https://github.com/andrelmartins/bigWig). Read counts within each TRE across all samples 
were then imported into DESeq2 1.22.2 (Love et al. 2014). Differential transcription analysis of 
TREs was performed with DESeq2 to identify TREs that were significantly differentially 
transcribed in iAs or MAs treated cells. 
4.2.8 TRE analyses 
TRE annotation was performed using the annotatePeaks.pl function from HOMER 
(Heinz et al. 2010) based on Ensembl Rn6 annotations. Transcription factor motif enrichment 
analysis was performed using the findMotifsGenome.pl function from HOMER using iAs -
specific TREs as peaks, “given” as the size parameter, and all TREs that were not identified as 




was performed following DESeq2 normalization of read counts quantified from each TRE or 
gene body as previously described. Clustering was performed in a pairwise manner using a 
correlation-based distance metric (1 -Spearman’s rho) using Ward’s minimum variance method. 
Proximal (-1000 to +100 bp from TSS) and distal TREs (the remaining TREs) were classified 
based on Ensembl Rn6 transcript annotations. ChIP-X analyses and KEGG pathway enrichment 
were performed using Enrichr (Chen et al. 2013a). 
4.2.9 RNA-seq analysis 
Read quality was assessed using FastQC. Reads were mapped to the rn6 genome with 
STAR 2.4.2a (Dobin et al. 2013). Transcripts were quantified with Salmon 0.8.2 (Patro et al. 
2017) using Ensemble Rn6 transcript annotations. Normalization was performed using DESeq2  
(Love et al. 2014).  
4.3 Results 
4.3.1 Glucose stimulated insulin secretion in INS-1 cells 
 To begin, I examined the effects of 24-hour exposure to 1 µM iAs or 0.5 µM MAs on 
insulin secretion by maintaining INS-1 832/13 cells for 1 hour in low glucose containing medium 
followed by stimulating for 2 hours with high glucose medium. Arsenic exposure was 
maintained for the duration of the glucose stimulation, and led to a significant decrease of insulin 
secretion in cells stimulated with 16.7 mM glucose (Fig. 4.1A). Secreted insulin was normalized 
to the amount of cellular protein to ensure the observed effects were not due to cell death. In 
addition, cell viability was measured using CellTox™ Green in which cells treated with digitonin 




exposed to 0.5 µM MAs exhibited a minor, but statistically significant reduction in cell viability 
(Fig. 4.1B). 
 
Figure 4.1:  Glucose stimulated insulin secretion by INS-1 832/13 cells (A) and cell viability (B) 
after 24-hour exposure to 1 µM iAs or 0.5 µM MAs. Data are represented as mean of 6-8 
replicates + SE for 3 or more independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 
treatment versus control high glucose stimulation or treatment versus control fluorescence. 
4.3.2 Identification of differentially expressed genes in INS-1 832/13 cells 
RNA sequencing was performed on INS-1 cells exposed to 1 µM iAs or 0.5 µM MAs to 
identify differentially expressed genes that are significantly altered by arsenic exposure. After 
aligning to a genome and counting reads, I performed differential expression analysis using 
DESeq2 (Love et al. 2014) . After DESeq2 analysis, I found 1148 significantly altered genes 
(599 genes upregulated and 549 downregulated; adjusted p < 0.05) in iAs exposed cells and 4037 
significantly altered genes (1879 upregulated and 2248 downregulated; adjusted p < 0.05) in 




and 3228 by MAs exposure, which I refer to as iAs-specific and MAs-specific genes 
respectively. In addition, I found 805 significantly altered genes in common between the two 
exposures. (Fig. 4.2C). Using the Enrichr analysis of the ChEA and KEGG databases I found 
that while iAs-specific genes are significantly over-represented in the Nfkb/RelA signaling 
pathway, MAs-specific genes are significantly over-represented in the FoxM1 signaling 
pathway. Both Nfkb and FoxM1 have been previously associated with beta cell function and 
identity. The 805 genes shared between the two exposures are enriched in the MAPK signaling 
pathway which has been shown to be activated in the presence of various stress stimuli including 





Figure 4.2: Identification of differentially expressed genes in iAs-and MAs-exposed cells (A) 
Heatmap of Euclidean distance between samples based on DESeq2 normalized gene expression 




principle components and the variance explained by each component. (B) Volcano plots 
displaying genes altered by 24-hr exposure to iAs (left) and MAs (right). Control, N = 2; iAs, 
N=2; MAs, N=2 (C) Results of ChIP-X enrichment analysis (ChEA) for genes unique to either 
iAs (left) or MAs (right) exposures, and KEGG pathway analysis (center) for genes affected by 
both iAs and MAs exposure  
4.3.3 Identification of transcriptional regulatory elements in INS-1 832/13 cells 
To identify TREs in INS-1 cells that may be altered by arsenic exposure, I performed 
matched ChRO-seq on INS-1 cells treated with iAs (N=2), MAs (N=2) or untreated “control” 
cells (N=2) (Fig. 4.3A). TREs were identified using dREG, a published algorithm that is able to 
identify transcriptional regulatory elements from run-on sequencing experiments such as GRO-
seq or ChRO-seq (Danko et al. 2015; Wang et al. 2019).  The majority of TREs are located in 
intergenic (29.85%) and promoter (24.48%) regions, with 19.28% located in intronic regions 
(Fig. 4.3B). TREs are 439.3 bp in length on average (Fig. 4.3C), which is in line with the 50-
1500 bp enhancer length proposed by previous studies (Blackwood and Kadonaga 1998; Parker 
et al. 2013). Hierarchical clustering demonstrated that transcription at TREs is sufficient to 
stratify iAs and MAs from untreated samples (Fig.4.3D). Furthermore, clustering based on 
transcription at only the distal TREs remains sufficient to stratify between iAs, MAs, and 
untreated cells. This data suggest that enhancer activity is condition-specific and uniquely altered 






Figure 4.3: Identification of differentially expressed TREs in iAs-and MAs-exposed cells (A) 
Diagram of ChRO-seq workflow. (B) The distribution of genomic locations of TREs identified 
by ChRO-seq. Genomic locations were defined by HOMER using Ensembl Rn6 GTF reference 
annotations. (C) Length distribution of TREs identified by ChRO-seq. (D) Heatmap of pairwise 
correlations from TRE transcription. Hierarchical clustering was performed using Euclidean 
distance and Ward’s minimum variance method. Color bar shows Spearman’s correlation 
coefficient. TREs were classified based on Ensembl Rn6 GTF annotations. 
4.3.4 Identification of iAs- or MAs-specific TREs in INS-1 cells 
 To identify TREs with altered activity in iAs or MAs treated cells as compared to 
untreated cells, I quantified read counts within each TRE across all samples and performed 
differential transcription analysis using DESeq2 (Love et al. 2014). I identified 89 TREs (9 up, 
80 down) with altered transcription in iAs exposed cells, and 647 TREs (312 up, 335 down) with 




factor motif enrichment analysis of downregulated TREs using the tool HOMER (Heinz et al. 
2010) revealed a significant enrichment in binding motifs for Pdx1 and Rfx6 in iAs-exposed 
cells (Fig. 4.4A). Both TFs have been previously established as critical in maintaining beta cell 
identity and in regulating the transcription, content, and secretion of insulin (Gao et al. 2014; 
Chandra et al. 2014). MAs exposure resulted in a decreased activity of TREs enriched in binding 
motifs for Pdx1 similarly to iAs, but also for NeuroD1 which regulates insulin gene expression 
(Itkin-Ansari et al. 2005) (Fig. 4.4A). Further analysis of MAs-specific TREs with increased 
activity revealed a significant enrichment for Nrf2 and Nfe2L2 binding sites (Fig. 4.4B). These 
findings are notable in that both Nrf2 and Nfe2L2 have been previously associated with 
oxidative stress response and reduced insulin secretion (Yang et al. 2012, 2017; Cui et al. 2017). 
In addition, Nrf2 has also been previously associated with iAs exposure in INS-1 cells (Fu et al. 
2010). Transcriptional regulation of TREs and genes involved in beta cell mass and 






Figure 4.4: Transcription factor motif enrichment in iAs or MAs-exposed cells (A) Table 
showing results of transcription factor motif enrichment in TREs downregulated in iAs (top) and 
MAs (bottom) compared to untreated cells. (B) Table showing results of transcription factor 
motif enrichment in TREs upregulated MAs compared to untreated cells. 
 
4.4 Discussion 
Exposure to iAs has been associated with an increased risk for the development of T2D as 
well as impaired pancreatic beta cell function. The metabolites of iAs, including trivalent MAs, 




proposed, the molecular foundations underlying T2D associated with iAs exposure remain 
unanswered.  
ChRO-seq aids in answering these questions by allowing us to directly measure nascent 
RNA transcription and create high-resolution maps of all the transcriptionally active RNA 
polymerases in cell or tissue. This process has several advantages over traditional RNA-seq 
analyses, which only measure the steady state level of a given RNA and provide no information 
on transcription, processing, or degradation. In contrast, ChRO-seq is able to measure the 
recruitment of all types of RNA polymerases and provides directional information. Additionally, 
ChRO-seq allows us to probe each of the individual steps of RNA transcription which include 
RNA polymerase recruitment, promoter-proximal pausing and transcription elongation. ChRO-
seq allows the concurrent study of all transcriptional events which include location and counts of 
protein-coding RNAs, long non-coding RNAs, regulatory elements such as eRNAs or promoters, 
and small non-coding microRNAs (Liu et al. 2017a).  Lastly, ChRO-seq allows researchers to 
directly assess transcription without the interference from splicing, capping, and post-
transcriptional stabilization. In my study, ChRO-seq allowed the characterization of the 
transcriptional landscape of INS-1 832/13 cells for the first time and facilitated the examination 
of the effects of arsenic exposure on regulatory elements that may contribute to complex diseases 
such as diabetes. 
In this chapter, I’ve carried out the first step to explore this area. I use ChRO-seq to map 
transcription and define transcriptional regulatory elements in rat insulinoma cells exposed to iAs 
or MAs as well as unexposed cells. With these data I have identified TREs that differentiate 
arsenic-exposed cells from unexposed, and also TREs that stratify cells exposed to iAs from 




altered TREs (647) than those altered by iAs exposure (89). While the observed disparity 
between exposures could be due to differential levels of cytotoxicity (Fig. 4.1B), the results also 
suggest that though exposures to either iAs or MAs result in a significant impairment of insulin 
secretion, each exposure may operate on distinct molecular targets to cause this impairment. 
Unique transcription factor binding motifs have been identified for iAs and MAs exposed cells 
along with the transcription factors predicted to bind at these sites. Exposure to iAs reduced the 
activity of TREs enriched in binding motifs for Rfx6 which regulates insulin transcription, 
content and secretion (Chandra et al. 2014) and for NeuroD1 in MAs-exposed cells, which 
controls insulin gene expression (Itkin-Ansari et al. 2005). Both exposures resulted in reduced 
activity of TREs enriched in binding motifs for Pdx1, a TF that is critical for establishing and 
maintaining β-cell identity (Gao et al. 2014). In addition, exposure to MAs increased the activity 
of TREs enriched in binding motifs for Nrf2 and NFE2L2. Previous literature has established 
Nrf2-mediated antioxidant response as a critical defense mechanism in pancreatic β-cells defense 
against acute cytotoxicity by arsenic (Fu et al. 2010; Yang et al. 2012). Additional literature has 
shown that Nfe2l2-deficient pancreatic β-cells display a muted antioxidant response which 
leaves them vulnerable to cellular damage induced oxidative stressors including arsenite (Cui et 
al. 2017). Increased activity of these TREs may therefore serve as a compensatory mechanism 
against the effects of MAs exposure. These altered TREs may represent a potential mechanistic 
links between arsenic exposure and diabetes.  
4.5 Limitations 
In the present study, we used the INS-1 832/13 cell line, which has been widely used in 
studies examining insulin secretion and the underlying mechanisms (Hohmeier et al. 2000a; Park 




were able to identify differential TRE activity using only two samples per treatment, future 
studies should strive to include more replicates in the experimental design. Transcriptional 
perturbations of were based on single concentrations of iAs and MAs after a single time point 
exposure.  Chromatin structure is highly complex and dynamic so discrete signals obtained at a 
single time point are not always sufficient to accurately describe changes in chromatin 
accessibility after an exposure.  
4.6 Conclusions and Future Directions 
The main findings in this work describe the effects of iAs or MAs exposures on TRE 
activity. The results of this study suggest that while exposure to iAs or MAs affects the activity 
of distinct TREs, both exposures are associated with decreased activity of TREs enriched in 
binding sites for important transcription factors critical in maintaining pancreatic beta cell 
identity and function, including Pdx1.  
The TREs identified by my ChRO-seq analyses represent potential sites of interest for further 
exploration. Functional in vitro and in vivo experiments will be necessary to determine the roles 
of these TREs in the detrimental arsenic-mediated effects in pancreatic beta cells. In addition, 
integrating my ChRO-seq/RNA-seq findings may be informative to connect differentially 
expressed genes to the enhancers that regulate them. Determining which genes may be driven 
primarily by transcriptional mechanisms or post-transcriptional modifications may allow 
researchers the ability to focus their attention on TFs, microRNAs, or other mechanisms that be 






CHAPTER 5: INTEGRATION AND FUTURE DIRECTIONS 
 
 Type 2 Diabetes is a complex metabolic disorder characterized by hyperglycemia. 
Chronic exposure to arsenic has been shown to interfere with many metabolic processes 
including insulin secretion, which may increase the risk of developing diabetes. A better 
understanding of how iAs contributes to the impairment of insulin secretion is essential for 
developing strategies to mitigate these harmful effects in humans. Additionally, the detection of 
early biomarkers of disease or exposure would allow researchers to identify and protect 
susceptible populations. The work presented here is a compilation of research that aimed to 
elucidate the relationship between arsenic exposure and impaired insulin secretion. 
In this dissertation, I have identified circulating miRNAs that may serve as potential 
biomarkers of arsenic exposure in the plasma of non-diabetic individuals, I have identified 
miRNAs that respond to iAs exposure in a cell-type specific manner, and I helped to further 
characterize the INS-1 832/13 transcriptional landscape by identifying promoters and enhancers 
that are altered by arsenic exposure. In this final chapter, I review the major conclusions from 
each previous chapter, discuss their implications, and propose future directions for each project.  
5.1 Arsenic-responsive miRNAs in human plasma 
In Chapter 2, I characterized the circulating miRNA profiles of non-diabetic individuals 




which may not accurately reflect the levels of arsenic in circulation or within target tissues. This 
study represents a major advancement for the research community by measuring As levels and 
speciation in plasma and associating them with circulating miRNAs in plasma. My analyses 
identified 6 plasma miRNAs which had been previously linked to cardiometabolic disease, as 
significantly associated with MAs, a metabolite of iAs. It is important to note that these 6 
miRNAs were identified in the plasma of healthy, non-diabetic individuals which may make 
them useful as early biomarkers of disease in individuals exposed to iAs and as potential early 
biomarkers of T2D.  
 While the identification of these miRNAs represents a notable advance, future studies 
should evaluate the utility and replication of these miRNA biomarkers in independent and large 
well-phenotyped cohorts exposed to iAs, or in patients diagnosed with T2D. Furthermore, 
longitudinal studies should be conducted to provide insight into the development of diabetes or 
other metabolic disorders in cohorts exposed to iAs, and whether changes in miRNAs in 
circulation could be useful as predictive early biomarkers of disease in otherwise healthy 
individuals. Analysis of circulating miRNAs could also be performed in large cohorts of 
prediabetic and diabetic individuals exposed to iAs. Those miRNAs identified in common 
between the two groups may represent potential markers for the early prediction of the 
conversion of prediabetic individuals to T2D patients.  
Interestingly, miRNAs are present in the circulation not as free molecules, but rather they 
are carried by extracellular vesicles (Hunter et al. 2008), such as exosomes, which are released 
by various cell types. They have been shown to mediate communication between cells and 
tissues. Communication between organs is central to the maintenance of glucose homoeostasis; 




associated complications. Aberrant levels of miR-320c isolated from urinary exosomes have 
already been identified and suggested as a candidate marker for diabetes complications, such as 
diabetic nephropathy (Delić et al. 2016), and so exosomal miRNAs may be more than just a 
useful source of biomarkers for early diagnosis of disease or prediction of disease progression.  
5.2 Arsenic-responsive miRNA and gene expression signatures in INS-1 cells 
In an effort to hone in on the mechanisms underlying iAs-associated metabolic disease, I 
focused on the in vitro characterization of arsenic exposure and impaired insulin secretion. By 
exposing the INS-1 832/13 cell line to As, I could directly measure the effect of exposure on 
insulin secretion and the resulting transcriptomic alterations. Studies from the Stýblo lab and 
others have shown that iAs and its methylated trivalent metabolites inhibit glucose-stimulated 
insulin secretion in pancreatic islets and β-cells (Fu et al. 2010; Douillet et al. 2013; Dover et al. 
2017, 2018). Since the mechanisms underlying this inhibition remain largely unknown, I 
investigated if impairments in insulin secretion were due to dysregulated miRNA expression.  
In Chapter 3, I first validated the previously cited studies by exposing INS-1 cells to iAs, 
Cd, and Mn. These three metals have all been linked to disrupted glucose homeostasis in 
published studies (Chen et al. 2009; Liu et al. 2016; Li et al. 2017) and shown to inhibit insulin 
secretion in recent studies from the Stýblo lab (Dover et al. 2018).  I next sought to identify 
changes in miRNA and gene expression that may be associated with this dysregulated insulin 
secretion. I began my work by trying to identify which miRNAs, if any, were altered by iAs 
exposure. Using small RNA sequencing, I identified changes to the miRNA profile that were 
specific to each exposure. Furthermore, I observed that iAs influences miRNA expression 




upregulated miRNA upon exposure to iAs treatment.  To my knowledge, miR-146 has not 
previously been connected with arsenic exposure, though it has been implicated with impaired 
insulin secretion (Roggli et al. 2010) in vitro. The expression of this miRNA is controlled by NF-
κB, a transcription factor involved in cytokine-mediated β-cell dysfunction and in the 
development of diabetes (Roggli et al. 2010).  
Interestingly, miR-146a increased in expression only after exposure to iAs but not MAs. 
This suggests that iAs and its metabolites may operate through different mechanisms and have 
unique effects on the gene expression landscape of β-cells. While I have run a few preliminary 
experiments to interrogate the role of miR-146a in pancreatic β-cells, more functional validation 
needs to be performed by overexpressing or knocking out miR-146a. In my experience, using 
LNA technology to perform a knock-down of miR-146a in INS-1 832/13 proved unsuccessful, 
though I was able to successfully knock-down other miRNAs. One potential explanation could 
be that if miR-146a is vital for the health of INS-1 832/13 cells, there may be compensatory 
mechanisms to up-regulate miR-146a quickly upon LNA-mediated suppression in order to 
protect against iAs-mediated cell damage. One possible way to study this is to use CRISPR/Cas9 
technology (Gilbert et al. 2013) to generate a miR-146a knock-out cell line to test the effects of 
iAs exposure on cell viability and insulin secretion.  
While miR-146a upregulation was observed to be associated with impaired insulin 
secretion in cell culture, the role of miR-146a in humans remains unclear. The deregulation of 
miR-146a has been repeatedly reported to be associated with T2D; however, the directionality 
(upregulation or down-regulation) is inconsistent across studies. A meta-analysis from 2017 of 
the current literature suggests that the downregulation of miR-146a could be associated with 




T2D is also observed in mouse studies in which miR-146a knockout mice displayed exaggerated 
weight gain, dysregulated blood glucose levels, and an increase in the activation of pro-
inflammatory genes as compared to control mice (Runtsch et al. 2019). In another study, 
administration of miR-146a mimics suppressed T2D-associated pro-inflammatory genes (Liu et 
al. 2017b). In contrast, miR-146a was found to be elevated in the pancreatic islets from diabetic 
obese mice and significantly affected β-cell survival and insulin exocytosis (Guay et al. 2011). In 
MIN6 cells, an insulin secreting β-cell line, cytokine exposure led to an induction of miR-146a 
due to activation of the transcription factor nuclear factor-κB (NF-κB) (Roggli et al. 2010), 
which is located upstream of the promoter of miR-146a.  Oxidative stress has been suggested as 
a potential link to β cell dysfunction through mechanisms involving activation of NF-κB, which 
also happens to be activated by low levels of arsenic exposure. Given the elevated expression of 
miR-146a after iAs exposure, it is possible that inflammation is an underlying process leading to 
impaired insulin secretion. Preliminary results of a pilot in vivo mouse experiment performed in 
the Stýblo lab suggest the observed upregulation of miR-146a in response of iAs in mouse 
pancreatic islets may be sex-specific (Supplementary Figure 2). One way to interrogate this 
observed relationship is to overexpress or knockdown miR-146 and measure metabolic 
parameters in a mouse model using both sexes. in an effort to recapitulate the results observed in 
the current study. Sequencing experiments to measure gene expression in the overexpression or 
knockout animals would allow us to identify any genes that are altered which may provide a clue 
to the mechanism by which iAs exerts its effects, and help us to identify new potential target 
genes of miR-146a.  
In addition to miR-146a, I identified several additional miRNAs that are drastically 




miR-29b-5p (upregulated), and miR-34a-5p (upregulated). While changes in miR-217 expression 
have not been directly studied in pancreatic beta cells, miR-217 has been identified in the serum 
of diabetic patients and contributes to the development of diabetic kidney disease by promoting 
chronic inflammation, renal fibrosis, and angiogenesis (Shao et al. 2017). The overexpression of 
miR-29b in MIN6 and dissociated islet cells led to impairment in glucose-stimulated insulin 
secretion, potentially due to decreasing the level of the antiapoptotic protein Mcl1 (Roggli et al. 
2012). Lastly, prolonged exposure of β-cells to proinflammatory cytokines has been shown to 
induce the expression of miR-34a (Roggli et al. 2010). Further interrogation using an in vivo 
mouse model is necessary to determine whether these miRNAs are contributing to the 
diabetogenic effects of iAs exposure seen in INS-1 cells, or merely regulated by iAs exposure 
through some yet to be discovered mechanism. 
Although the primary focus of this portion of the dissertation focused on miRNAs, gene 
expression is also a major piece of the puzzle that is important to address. Genes down-regulated 
by iAs with roles in beta cell function, which include Camk2a, a predicted target of miR-146a, 
may represent potential targets for therapeutic intervention. Previous studies have implicated iAs 
exposure in reduced calcium influx (Díaz-Villaseñor et al. 2008; Huang et al. 2019), which may 
be mediated in part through the inhibition of Camk2a. Future studies should focus on further 
functional characterization of Camk2a to determine whether its suppression contributes to 
reduced GSIS in the context of iAs exposure.  
5.3 Enhancer profiling of arsenic exposure in INS-1 cells 
In Chapter 4, I used ChRO-seq to define genome-wide enhancer profiles in INS-1 cells. 




(TREs) that are significantly more active and over 400 TREs less active in iAs or MAs exposed 
cells than unexposed cells. The genes and TREs identified by my ChRO-seq analyses represent 
potential genomic sites of interest for further exploration. Functional in vitro and in vivo 
experiments will be necessary to determine what these genes or TREs are contributing to the 
observed arsenic-mediated effects in pancreatic beta cells. Future work should aim to integrate 
the ChRO-seq and RNA-seq findings to connect differentially expressed genes to the enhancers 
that regulate them. Knocking out enhancers of interest using CRISPR/Cas9 technology (Gilbert 
et al. 2013) could be used as a potential strategy to interrogate enhancer function. As enhancers 
function through the action of transcription factors, it will also be informative to identify the 
specific transcription factors vital to enhancer-promoter interactions and perform knock-down or 
overexpression experiments. The TREs identified with reduced activity after exposure to iAs or 
MAs are enriched for motifs of Pdx1, Rfx6, and NeuroD1. These findings are notable in that 
both Pdx1 and Rfx6 have been previously established as critical in maintaining beta cell identity 
and in regulating the transcription, content, and secretion of insulin (Gao et al. 2014; Chandra et 
al. 2014) while NeuroD1 regulates insulin gene expression (Itkin-Ansari et al. 2005). These 
results represent provide us with several candidate transcription factors worth pursuing for 
further analysis.  
Lastly, determining which genes may be driven primarily by transcriptional mechanisms or 
post-transcriptional modifications may allow researchers the ability to focus their attention on 
TFs, microRNAs, or other mechanisms that could be worth functionally validating. Once 
potential mechanisms are identified, applying ChRO-seq to a mouse model exposed to iAs would 




5.4 Identification of novel therapeutic targets / relevance to diabetes 
In the studies from chapters 3 and 4, I used the INS-1 832/13 cell line which has been 
widely used in studies examining insulin secretion and the underlying mechanisms (Hohmeier et 
al. 2000a; Park et al. 2007; Skelin et al. 2010; Lorenz et al. 2013; Dover et al. 2017). In these 
studies, inhibition of glucose-stimulated secretion in vitro exposure to iAs and its metabolites 
(Dover et al. 2017) was consistent with beta-cell dysfunction, as measured by low fasting plasma 
insulin, reported in epidemiologic studies carried out in populations exposed to iAs (Del Razo et 
al. 2011; Mendez et al. 2016a). Still, translatability of current findings to human conditions 
remains uncertain. Using a more relevant beta cell line may help. There is currently a human 
pancreatic beta cell line, the EndoC-βH1 (Gurgul-Convey et al. 2015), that could be used moving 
forward. These cells are reported to strongly resemble human islet beta cells in terms of glucose 
and incretin stimulated insulin secretion capabilities (Tsonkova et al. 2018), as well as overall 
molecular profile (Lawlor et al. 2019).  
While I have focused my research on beta cells and their relationship with arsenic, it is 
imperative that the field does not disregard the contributions of other cell types and tissues in the 
development of diabetes. Cross-talk between tissues is critical for the maintenance of glucose 
homeostasis and for overall health. Future studies should focus on the translation of these INS-1 
832/13 findings within in vivo models. It should be noted that there are difficulties and 
limitations with using traditional model organisms such as rats or mice to study the effects of iAs 
exposure. For example, the rate of iAs metabolism and excretion varies greatly between humans 
and other species. For example, in humans and most animals DMAs are rapidly eliminated from 
the body; however, in rats DMAs accumulate in erythrocytes due to the strong affinity for rat 




reactive intermediate that may cause damage to the urinary tract and bladder. In contrast, mice 
metabolize iAs much more efficiently than humans do. As a result, mice have to be exposed to 
very high concentrations of iAs to emulate the effects seen in humans. As a result of the highly 
efficient metabolism, the levels of methylated metabolites of iAs in circulation differ greatly 
from the levels observed in humans. Taken together, neither rat or mouse models may be ideal to 
predict the human risk associated with arsenic exposure. A very recent humanized mouse model 
has been developed by researchers at UNC and is currently being tested which mimics the 
metabolism and adverse effects of iAs exposure observed in humans. Future studies should move 
toward this specific model and away from traditional mouse models in the study of iAs exposure.  
5.5 Dissertation contribution 
In this dissertation, I have examined the association between iAs exposure and altered 
profiles of circulating miRNAs in a human cohort, and identified 6 circulating plasma miRNAs 
that are associated with plasma concentration of MAs, a toxic metabolite of iAs. In addition, I 
have explored the relationship between insulin secretion and altered transcriptomic profiles in 
pancreatic beta cells exposed to arsenic. The work presented here was generated by using both 
molecular and computational approaches, and provides novel findings regarding the effects of 
iAs exposure on the transcriptional program as well as gene and miRNA expression landscape of 
rat insulinoma cells. The results and data presented here offer strong rationale for continued 
investigation of the key molecular drivers of the effects of arsenic exposure. Though many 
unanswered questions remain regarding the interaction between arsenic, transcriptional 
alterations, and insulin secretion, it is my hope that the research presented here advances the field 





APPENDIX 1: SUPPLEMENTAL FIGURES AND TABLES 
 
Supplemental Figure 1: Chapter 2 Read Length Distributions 
RNA from a total of 109 healthy control samples was sequenced as discussed in Chapter 2. 
Length distribution plots depict a peak at ~22 nt in length that represents miRNAs. Lack of a 

















Supplemental Table 1:  Chapter 2 Mapping Stats 


















102_ZimFBP_S42_L003_R1_001 3E+07 1.9E+07 71.97 77.92 17.55 3.41 15.6 
105_ZimFBP_S12_L001_R1_001 2E+07 1.5E+07 59.11 58.33 30.25 2.39 4.7 
10_LagFBP_S37_L003_R1_001 2E+07 1.2E+07 50.19 38.87 5.9 1.35 6.27 
111_ZimFBP_S99_L007_R1_001 2E+07 1.1E+07 61.68 74.97 28.83 2.19 11.6 
112_ZimFBP_S6_L008_R1_001 2E+07 1.6E+07 65.98 52.49 23.67 1.71 5 
114_ZimFBP_S9_L008_R1_001 3E+07 2E+07 68.17 66.78 31.29 1.44 5.85 
116_ZimFBP_S96_L007_R1_001 2E+07 1.4E+07 59.7 68.61 28.86 3.55 9.08 
118_ZimFBP_S14_L008_R1_001 3E+07 2.2E+07 79 84.48 35.01 2.27 10.34 
119_ZimFBP_S19_L002_R1_001 2E+07 1.8E+07 72.08 73.36 23.69 2.55 13.12 
11_LagFBP_S40_L003_R1_001 2E+07 9705644 45.12 58 14.07 1.68 7.13 
120_ZimFBP_S35_L003_R1_001 2E+07 1.3E+07 67.31 66.47 30.64 3.22 7.22 
127_ZimFBP_S27_L003_R1_001 2E+07 1.6E+07 72.65 72.56 21.78 0.99 11.65 
128_ZimFBP_S13_L001_R1_001 2E+07 1.4E+07 66.69 67.77 29.36 3.52 9.75 
129_ZimFBP_S88_L006_R1_001 2E+07 1.2E+07 49.69 59.77 33.2 1.21 7.29 
12_LagFBP_S52_L004_R1_001 3E+07 1.2E+07 44.58 48.16 8.46 1.29 3.94 
12_ZimFBP_S28_L002_R1_001 2E+07 1.6E+07 66.9 65.66 28.58 2.5 9.25 
132_ZimFBP_S38_L003_R1_001 2E+07 1.8E+07 71.81 72.04 31.19 2.97 8.36 
136_ZimFBP_S12_L008_R1_001 1E+07 4059530 38.1 52.51 11.51 6.99 3.79 
139_ZimFBP_S69_L005_R1_001 3E+07 1.9E+07 65.2 71.51 25.44 3.9 9.88 
13_ZimFBP_S24_L002_R1_001 2E+07 1.6E+07 62.67 70.44 20.55 5.86 11.63 
140_ZimFBP_S39_L003_R1_001 2E+07 1.1E+07 60.15 50.59 20.3 1.71 6.88 
144_ZimFBP_S79_L006_R1_001 3E+07 1.3E+07 51.49 51.04 18.18 1.94 6.9 
147_ZimFBP_S36_L003_R1_001 2E+07 9372190 56.79 41.33 18.15 2.54 4.66 
149_ZimFBP_S33_L003_R1_001 2E+07 1.6E+07 71.32 71.77 32.15 3.7 7.18 
14_LagFBP_S117_L008_R1_001 2E+07 1.3E+07 56.48 66.89 11.71 2.61 12.21 
151_ZimFBP_S30_L002_R1_001 2E+07 1.5E+07 63.67 72.64 19.44 3.16 14.15 
16_LagFBP_S118_L008_R1_001 2E+07 1.1E+07 53.35 42.17 8.21 1.1 8.8 




17_LagFBP_S115_L008_R1_001 2E+07 1.1E+07 49.98 42.13 15.63 1.99 4.2 
19_LagFBP_S39_L003_R1_001 2E+07 1.4E+07 57.07 50.25 16.95 1.25 8.48 
1_LagFBP_S22_L002_R1_001 2E+07 1.6E+07 63.84 42.62 7.88 1.3 6.6 
1_ZimFBP_S7_L008_R1_001 2E+07 1.2E+07 57.82 60.03 23.45 1.97 6.19 
20_ZimFBP_S10_L001_R1_001 3E+07 1.9E+07 67.57 68.41 24.41 2.74 10.71 
21_ZimFBP_S1_L001_R1_001 2E+07 1.7E+07 66.71 73.52 27.01 4.78 9.59 
24_ZimFBP_S25_L002_R1_001 3E+07 1.7E+07 64.16 72.72 17.76 9.73 8.49 
25_ZimFBP_S15_L008_R1_001 4E+07 1.3E+07 35.92 49.97 9.75 15.49 1.82 
26_LagFBP_S97_L007_R1_001 2E+07 1.2E+07 54.72 56.52 15.47 1.48 9.25 
26_ZimFBP_S48_L004_R1_001 2E+07 8324293 44.27 50.35 11.48 2.17 9.51 
28_ZimFBP_S3_L001_R1_001 2E+07 1.7E+07 73.37 81.15 26.84 2.4 13.05 
2_LagFBP_S31_L003_R1_001 2E+07 1.4E+07 60.67 36.47 6.35 1.75 5.65 
2_ZimFBP_S7_L001_R1_001 3E+07 1.8E+07 65.51 64.93 17.36 1.78 12.69 
32_ZimFBP_S29_L003_R1_001 3E+07 2.1E+07 78.94 82.68 45.13 3.89 7.92 
33_LagFBP_S64_L005_R1_001 2E+07 1.3E+07 54.79 60.96 20.81 3.55 8.27 
33_ZimFBP_S30_L003_R1_001 6E+07 1.6E+07 27.93 36.74 5.03 1.33 1.16 
35_LagFBP_S103_L007_R1_001 4E+07 2.5E+07 61.62 51.8 9.2 1.04 10.11 
3_LagFBP_S36_L003_R1_001 3E+07 1.5E+07 58.19 47.06 8.73 1.12 10.98 
41_LagFBP_S105_L007_R1_001 2E+07 1.3E+07 60.44 64.05 23.55 1.59 7.98 
42_LagFBP_S106_L008_R1_001 2E+07 1.3E+07 64.98 70.3 17.6 2.99 13.29 
42_ZimFBP_S16_L002_R1_001 2E+07 1.2E+07 63.98 60.26 27.3 2.26 8.47 
43_ZimFBP_S4_L001_R1_001 3E+07 2.2E+07 82.72 87.88 27.55 4.19 13.15 
45_ZimFBP_S46_L004_R1_001 3E+07 2.2E+07 76.88 84.33 25.47 3.63 14.66 
46_LagFBP_S90_L006_R1_001 3E+07 1.9E+07 69.79 82.94 17.68 1.06 15.18 
46_ZimFBP_S6_L001_R1_001 2E+07 1.5E+07 67 72.27 28.59 2.54 11.99 
47_ZimFBP_S4_L008_R1_001 3E+07 2E+07 66.64 71.67 29.02 2.58 7.58 
48_LagFBP_S94_L007_R1_001 2E+07 1.5E+07 67.94 67.48 18.47 0.95 13.45 
48_ZimFBP_S93_L007_R1_001 2E+07 8609035 45.88 46.17 28.8 2.07 3.09 
50_ZimFBP_S10_L008_R1_001 3E+07 7357589 27.61 39.44 4.48 4.03 0.88 
52_LagFBP_S87_L006_R1_001 3E+07 2.3E+07 83.74 91.39 19.74 0.62 17.28 
52_ZimFBP_S1_L008_R1_001 2E+07 1.7E+07 69.87 74.98 31.42 3.97 9.26 
55_ZimFBP_S15_L001_R1_001 3E+07 1.6E+07 59.29 62.99 17.89 4.49 11.16 
56_LagFBP_S57_L004_R1_001 3E+07 2.1E+07 73.81 79.88 22.92 1.49 14.61 




60_LagFBP_S75_L005_R1_001 3E+07 9360039 30.07 56.59 10.58 1.75 4.57 
62_LagFBP_S67_L005_R1_001 2E+07 1.4E+07 62.15 57.22 12.11 4.06 7.68 
62_ZimFBP_S49_L004_R1_001 3E+07 1.9E+07 70.52 74.5 25.09 6.06 10.55 
63_ZimFBP_S91_L007_R1_001 2E+07 1.3E+07 53.91 67.59 31.33 1.81 7.06 
65_LagFBP_S66_L005_R1_001 3E+07 1.9E+07 71.97 73.43 34.46 1.07 5.87 
65_ZimFBP_S89_L006_R1_001 3E+07 2E+07 72.95 80.26 25.53 7.87 10.85 
66_ZimFBP_S41_L003_R1_001 3E+07 1.8E+07 64.47 60.75 37.66 2.1 4.08 
67_LagFBP_S58_L004_R1_001 2E+07 1.4E+07 63.01 67.64 21.11 0.88 12.65 
68_LagFBP_S73_L005_R1_001 2E+07 1.2E+07 56.51 62 18.79 1.09 10.59 
70_LagFBP_S76_L006_R1_001 1E+07 1396551 11.28 35.8 11.66 0.75 5.94 
70_ZimFBP_S100_L007_R1_001 3E+07 2.3E+07 67.51 76.51 19.75 5.13 13.68 
71_ZimFBP_S33_L003_R1_001 3E+07 1.8E+07 64.67 72.99 21.15 2.41 13.15 
72_LagFBP_S60_L004_R1_001 2E+07 1.5E+07 64.12 69.06 20.06 0.88 11.76 
72_ZimFBP_S51_L004_R1_001 3E+07 2.2E+07 77.59 85.63 19.18 5.34 15.86 
75_ZimFBP_S3_L008_R1_001 9E+06 5842523 67.45 71.69 37.84 1.15 6.41 
76_LagFBP_S72_L005_R1_001 3E+07 1.6E+07 62.16 67.88 25.32 1.42 11.05 
76_ZimFBP_S32_L003_R1_001 3E+07 1.9E+07 75.65 72.97 28.98 1.98 9.45 
77_LagFBP_S82_L006_R1_001 2E+07 8752712 41.22 53.29 13.52 0.88 11.33 
78_LagFBP_S81_L006_R1_001 2E+07 1.4E+07 58.16 69.38 18.48 0.87 12.1 
7_LagFBP_S120_L008_R1_001 3E+07 1.6E+07 62.57 63.81 34.12 0.72 3.48 
82_LagFBP_S70_L005_R1_001 3E+07 1.6E+07 58.44 66.33 27.76 3.49 7.27 
86_LagFBP_S84_L006_R1_001 2E+07 1.1E+07 48.72 54.15 18.9 1.44 8.9 
86_ZimFBP_S18_L002_R1_001 2E+07 1.5E+07 72.56 81.08 36.43 2.15 8.88 
88_ZimFBP_S34_L003_R1_001 3E+07 2E+07 66.76 59.21 15.13 3.32 11.2 
90_LagFBP_S109_L008_R1_001 3E+07 1.3E+07 43.4 46.2 18.68 2.79 3.1 
91_LagFBP_S45_L003_R1_001 2E+07 9797319 43.27 39.21 11.43 1.19 3.02 
92_LagFBP_S108_L008_R1_001 1E+07 2686095 25.99 28.3 13.63 0.97 6.06 
94_LagFBP_S111_L008_R1_001 2E+07 6066454 30.73 39.54 10.92 2.23 5.23 
95_LagFBP_S112_L008_R1_001 2E+07 3454543 20.92 31.57 8.15 1.21 2.39 
95_ZimFBP_S9_L001_R1_001 2E+07 1.6E+07 65.59 70.71 26.06 5.79 9.59 
96_LagFBP_S55_L004_R1_001 2E+07 1E+07 46.71 43.15 14.8 1.86 4.95 
96_ZimFBP_S43_L003_R1_001 2E+07 1.5E+07 62.32 73.32 26.08 4.41 10.91 
98_ZimFBP_S21_L002_R1_001 3E+07 1.6E+07 54.03 58.83 24.67 3.87 6.21 




Lag34_S20 2E+07 1.5E+07 64.28 60.97 32.35 0.94 4.54 
Lag54_S6 5E+07 3.2E+07 67.26 72.34 31.63 0.75 7.09 
Lag83_S15 3E+07 1.7E+07 53.3 58.46 25.95 0.95 5.86 
Zim109_S1 2E+07 5395962 32.15 44.05 8.1 4.89 0.83 
Zim11_S5 4E+07 2.6E+07 59.69 73.69 42.71 0.84 3.54 
Zim131_S3 2E+07 1.5E+07 62.28 59.12 29.57 0.76 4.64 
Zim3_S4 3E+07 2E+07 59.76 52.98 28.1 0.73 1.89 
Zim49_S21 3E+07 2.1E+07 70.6 79.15 41.86 1.1 3.21 
Zim53_S11 4E+07 3.2E+07 73.27 82.99 39.42 1.84 8.03 
Zim56_S23 5E+07 3.8E+07 73.83 70.03 44.78 2.9 5.3 
Zim64_S19 6E+07 4.6E+07 74.11 79.42 53.14 1.55 4.67 
Zim87_S17 5E+06 2892097 61.31 63.78 38.78 0.71 2.79 






Supplementary Table 2: MiRNA associations with plasma arsenicals in Chapter 2 
After normalization, all sequencing reads were transformed with a Box-Cox transformation. 
(Package ‘car’; RStudio Version 1.0.136) and all plasma measurements were log-transformed.  
The association between plasma As levels and miRNA expression levels were evaluated in 
samples using a separate general linear regression model for each species of arsenic against each 
miRNA, where the plasma As species was set as the independent variable and looped through 
each plasma miRNA as the dependent variable. The regression model included covariates that 
may be related to miRNA expression levels such as age (continuous), sex (categorical), body 
mass index (BMI) (continuous), smoking status (categorical), and alcohol consumption status 
(categorical).  
Significant associations (#) between miRNA expression and plasma As were classified as having 
a P-value < 0.05 (P) and a false discovery rate adjusted p-value (Q) <0.15 using an analysis of 
covariance (ANCOVA) model. 
miRNA Plasma Total As Plasma MAs Plasma iAs Plasma DMAs 
 
# P Q  # P Q # P Q # P Q 
hsa_mir_423_5p 0.314 0.017 0.342 0.356 0.002 0.139 - - - 0.335 0.007 0.248 
hsa_mir_26a_2_5p -0.292 0.034 0.342 -0.302 0.015 0.210 - - - -0.274 0.037 0.248 
hsa_mir_26a_1_5p -0.294 0.033 0.342 -0.301 0.015 0.210 - - - -0.273 0.037 0.248 
hsa_mir_126_5p -0.303 0.026 0.342 -0.288 0.018 0.210 - - - -0.290 0.024 0.248 
hsa_mir_30d_5p -0.311 0.032 0.342 -0.351 0.007 0.210 - - - -0.311 0.024 0.248 
hsa_mir_142_5p___2 -0.385 0.005 0.342 -0.395 0.001 0.126 - - - -0.420 0.001 0.248 
hsa_mir_26b_5p -0.282 0.047 0.363 -0.282 0.027 0.210 - - - -0.292 0.030 0.248 
hsa_mir_30e_5p -0.296 0.034 0.342 -0.313 0.012 0.210 - - - -0.326 0.014 0.248 
hsa_mir_191_5p_+_1 -0.262 0.046 0.362 -0.241 0.042 0.211 - - - -0.271 0.029 0.248 
hsa_mir_320b_1 0.283 0.031 0.342 0.266 0.024 0.210 - - - 0.269 0.031 0.248 
hsa_mir_320b_2 0.294 0.025 0.342 0.275 0.019 0.210 - - - 0.278 0.025 0.248 
hsa_mir_26a_2_5p___1 -0.349 0.017 0.342 -0.354 0.007 0.210 - - - -0.333 0.017 0.248 
hsa_mir_26a_1_5p___1 -0.346 0.018 0.342 -0.355 0.007 0.210 - - - -0.334 0.016 0.248 
hsa_mir_629_5p 0.301 0.028 0.342 0.255 0.040 0.211 - - - 0.315 0.015 0.248 
hsa_mir_155_5p -0.403 0.007 0.342 -0.387 0.004 0.210 - - - -0.364 0.011 0.248 
hsa_mir_126_5p_+_1 -0.290 0.028 0.342 -0.252 0.035 0.211 - - - -0.285 0.023 0.248 
hsa_mir_30d_5p_+_1 -0.341 0.010 0.342 -0.325 0.006 0.210 - - - -0.304 0.015 0.248 
hsa_mir_126_3p_+_1 -0.317 0.021 0.342 -0.297 0.016 0.210 - - - -0.304 0.019 0.248 
hsa_mir_26a_2_5p_+_1 -0.278 0.042 0.355 -0.273 0.026 0.210 - - - - - - 
hsa_mir_30c_2_5p -0.298 0.023 0.342 -0.257 0.030 0.211 - - - -0.267 0.032 0.248 
hsa_mir_30c_1_5p -0.301 0.023 0.342 -0.253 0.034 0.211 -0.226 0.042 0.885 -0.264 0.036 0.248 
hsa_mir_17_5p -0.366 0.010 0.342 -0.332 0.009 0.210 - - - -0.359 0.007 0.248 
hsa_mir_199a_2_3p___1 -0.301 0.037 0.342 -0.290 0.025 0.210 - - - -0.285 0.037 0.248 
hsa_mir_199a_1_3p___1 -0.301 0.036 0.342 -0.291 0.025 0.210 - - - -0.285 0.037 0.248 
hsa_mir_199b_3p___1 -0.302 0.036 0.342 -0.289 0.026 0.210 - - - -0.283 0.039 0.248 
hsa_mir_20a_5p -0.284 0.041 0.355 -0.319 0.010 0.210 - - - -0.302 0.021 0.248 




hsa_mir_320c_2 0.332 0.008 0.342 0.366 0.001 0.126 - - - 0.300 0.012 0.248 
hsa_mir_486_5p_+_1 0.380 0.009 0.342 0.294 0.025 0.210 0.311 0.010 0.885 0.309 0.025 0.248 
hsa_mir_342_3p -0.304 0.030 0.342 - - - -0.232 0.049 0.885 -0.273 0.040 0.248 
hsa_mir_543 -0.299 0.042 0.355 - - - - - - - - - 
hsa_mir_215 -0.289 0.045 0.362 -0.279 0.031 0.211 - - - -0.276 0.044 0.253 
hsa_mir_30b_5p -0.266 0.043 0.355 -0.251 0.034 0.211 - - - -0.261 0.036 0.248 
hsa_mir_130b_5p -0.301 0.026 0.342 - - - -0.270 0.017 0.885 - - - 
hsa_mir_142_5p_+_1 -0.350 0.020 0.342 -0.347 0.010 0.210 - - - -0.284 0.047 0.253 
hsa_mir_133a_1 -0.336 0.032 0.342 -0.320 0.023 0.210 - - - - - - 
hsa_mir_133a_2 -0.328 0.037 0.342 -0.327 0.020 0.210 - - - -0.296 0.047 0.253 
hsa_mir_454_5p -0.368 0.007 0.342 -0.397 0.001 0.126 - - - -0.351 0.006 0.248 
hsa_let_7i_5p___1 -0.351 0.024 0.342 -0.364 0.009 0.210 - - - -0.333 0.024 0.248 
hsa_mir_320b_1_+_1 0.276 0.030 0.342 0.245 0.033 0.211 - - - 0.251 0.038 0.248 
hsa_mir_320b_2_+_1 0.295 0.022 0.342 0.258 0.026 0.210 - - - 0.257 0.036 0.248 
hsa_mir_320b_1___1 0.298 0.021 0.342 0.264 0.023 0.210 - - - 0.269 0.028 0.248 
hsa_mir_320b_2___1 0.290 0.025 0.342 0.268 0.021 0.210 - - - 0.275 0.025 0.248 
hsa_mir_24_2_5p___1 -0.324 0.024 0.342 -0.356 0.006 0.210 - - - -0.292 0.033 0.248 
hsa_mir_320d_1 0.279 0.040 0.355 0.290 0.017 0.210 - - - - - - 
hsa_mir_598 -0.318 0.025 0.342 -0.322 0.011 0.210 - - - -0.300 0.025 0.248 
hsa_mir_486_5p_+_2 - - - 0.272 0.040 0.211 - - - 0.282 0.044 0.253 
hsa_mir_25_3p - - - -0.289 0.019 0.210 - - - -0.258 0.049 0.256 
hsa_mir_16_1_5p - - - -0.272 0.027 0.210 - - - -0.297 0.022 0.248 
hsa_mir_16_2_5p - - - -0.277 0.025 0.210 - - - -0.302 0.020 0.248 
hsa_mir_451a - - - -0.255 0.042 0.211 - - - -0.277 0.036 0.248 
hsa_mir_21_5p - - - -0.245 0.049 0.234 - - - -0.270 0.039 0.248 
hsa_mir_146b_5p - - - -0.266 0.038 0.211 - - - - - - 
hsa_mir_423_5p_+_1 - - - 0.384 0.002 0.139 - - - 0.337 0.012 0.248 
hsa_mir_93_5p - - - -0.290 0.022 0.210 - - - -0.279 0.037 0.248 
hsa_mir_27b_3p - - - -0.301 0.020 0.210 - - - -0.279 0.041 0.249 
hsa_mir_30e_5p_+_1 - - - -0.296 0.030 0.211 - - - -0.328 0.023 0.248 
hsa_mir_142_5p - - - -0.291 0.029 0.211 - - - - - - 
hsa_mir_151a_3p___2 - - - -0.277 0.025 0.210 - - - -0.258 0.049 0.256 
hsa_mir_16_2_3p___1 - - - -0.266 0.039 0.211 - - - -0.284 0.036 0.248 
hsa_mir_16_1_5p_+_1 - - - -0.258 0.035 0.211 - - - -0.288 0.025 0.248 
hsa_mir_16_2_5p_+_1 - - - -0.261 0.032 0.211 - - - -0.291 0.023 0.248 
hsa_mir_223_3p - - - -0.255 0.037 0.211 - - - -0.266 0.040 0.248 
hsa_mir_106b_3p - - - -0.272 0.039 0.211 - - - - - - 
hsa_mir_26a_1_5p_+_1 - - - -0.248 0.041 0.211 - - - - - - 
hsa_mir_30e_3p - - - -0.297 0.016 0.210 - - - -0.267 0.040 0.248 
hsa_mir_101_2_3p___1 - - - -0.253 0.046 0.225 - - - - - - 
hsa_mir_101_1_3p___1 - - - -0.242 0.045 0.224 - - - - - - 
hsa_mir_671_3p - - - -0.275 0.032 0.211 - - - - - - 
hsa_mir_181c_5p - - - -0.275 0.036 0.211 - - - -0.286 0.039 0.248 
hsa_mir_421 - - - -0.265 0.031 0.211 - - - -0.266 0.040 0.248 






hsa_mir_19b_1_3p - - - -0.272 0.035 0.211 - - - -0.289 0.033 0.248 
hsa_mir_324_5p - - - -0.315 0.022 0.210 - - - -0.326 0.024 0.248 
hsa_mir_181a_1_3p - - - -0.298 0.023 0.210 - - - - - - 
hsa_mir_99b_5p_+_1 - - - 0.288 0.021 0.210 - - - 0.305 0.020 0.248 
hsa_mir_199a_1_5p - - - -0.233 0.041 0.211 - - - - - - 
hsa_mir_199a_2_5p - - - -0.236 0.038 0.211 - - - - - - 
hsa_mir_942 - - - -0.265 0.047 0.225 - - - - - - 
hsa_mir_484 - - - - - - -0.234 0.048 0.885 - - - 
hsa_mir_363_3p - - - - - - 0.255 0.035 0.885 - - - 
hsa_mir_1180 - - - - - - 0.277 0.021 0.885 - - - 
hsa_mir_200a_3p - - - - - - 0.286 0.025 0.885 - - - 
hsa_mir_484___1 - - - - - - -0.248 0.036 0.885 - - - 
hsa_mir_148b_3p_+_1 - - - - - - -0.263 0.038 0.885 - - - 
hsa_mir_425_5p - - - - - - - - - -0.272 0.026 0.248 
hsa_mir_185_5p - - - - - - - - - -0.272 0.045 0.253 
hsa_mir_21_5p_+_1 - - - - - - - - - -0.268 0.046 0.253 
hsa_mir_451a_+_1 - - - - - - - - - -0.275 0.033 0.248 
hsa_mir_26b_5p___1 - - - - - - - - - -0.271 0.047 0.253 




Supplemental Table 3: Chapter 3 Small RNA Mapping Statistics 
Mapping statistics generated by miRquant for samples discussed in Chapter 3.  
 
  
















































































18.33 19.68 19.34 24.79 20.42 21.33 22.91 23.83 25.41 21.25 22.43 19.2 


























% Exact matches 
84.28 85.15 85.11 85.49 85.11 84.94 85.22 85.35 84.72 85.27 85.4 85.12 
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78.94 80.66 80.44 81.05 80.42 79.85 79.52 80.1 79.18 80.82 80.93 80.43 
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Supplemental Figure 2: Chapter 3 Supplementary 
(A) Scatter plot of miRNA expression values in the islets of female mice with untreated 
expression on the x-axis and treated expression values on the y-axis. The dotted lines represent a 
fold change of +/- 1.5. (B) Volcano plot displaying genes altered in the islets of male mice 
exposed to 100 ppb iAs in drinking water. The vertical lines represent a fold change of +/- 1.5, 
and the horizontal line is a significance value of an adjusted p=0.05; (Control, N = 3; 100 ppb 
iAs, N=3) (C) Bar graphs quantifying the expression of miR-146a in (A) and (B). Expression is 
plotted as reads per million miRs mapped (RPMMM) and error bars represent the standard 
deviation between samples. (Control male N=3, 100 ppb iAs male N=3; Control female N=1, 
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